```
=> d his

     (FILE 'HOME' ENTERED AT 12:08:40 ON 19 JAN 2010)

     FILE 'CAPLUS' ENTERED AT 12:08:51 ON 19 JAN 2010
L1          3420 S OLANZAPINE
L2        705219 S PRECIP?
L3            41 S L1 AND L2
L4             2 S PRECIPTATE/IT
L5         17536 S PRECIPITATE/IT
L6             1 S L1 AND L5

     FILE 'REGISTRY' ENTERED AT 12:10:18 ON 19 JAN 2010
L7             1 S OLANZAPINE/CN
L8             1 S 132539-06-1/RN

     FILE 'REGISTRY' ENTERED AT 12:11:57 ON 19 JAN 2010
L9                STR 132539-06-1
L10          111 S L9 FAM FUL

     FILE 'HCAPLUS' ENTERED AT 12:12:39 ON 19 JAN 2010
L11       144033 S (CRYST?) AND (POLYMORPH? OR POLYTYP? OR POLYSTRUCTUR? OR DIMO

     FILE 'REGISTRY' ENTERED AT 12:13:35 ON 19 JAN 2010
                SELECT CHEM L10 1-
                DEL SEL Y
                SEL CHEM L10
L12             QUE E2-131

     FILE 'HCAPLUS' ENTERED AT 12:17:27 ON 19 JAN 2010
L13         3496 S L12

     FILE 'REGISTRY' ENTERED AT 12:24:43 ON 19 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 12:25:38 ON 19 JAN 2010

     FILE 'REGISTRY' ENTERED AT 12:26:07 ON 19 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 12:27:33 ON 19 JAN 2010
                SELECT RN L*** 1-

     FILE 'REGISTRY' ENTERED AT 12:28:11 ON 19 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 12:28:58 ON 19 JAN 2010
                S C17 H20 N4 S/MF

     FILE 'REGISTRY' ENTERED AT 12:29:47 ON 19 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 12:29:47 ON 19 JAN 2010

     FILE 'REGISTRY' ENTERED AT 12:30:18 ON 19 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 12:30:51 ON 19 JAN 2010

     FILE 'REGISTRY' ENTERED AT 12:40:52 ON 19 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 12:41:11 ON 19 JAN 2010
```

```
     FILE 'REGISTRY' ENTERED AT 12:44:43 ON 19 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 12:46:03 ON 19 JAN 2010

     FILE 'REGISTRY' ENTERED AT 12:50:22 ON 19 JAN 2010
L14           0 S L10 AND AMORPHOUS

     FILE 'HCAPLUS' ENTERED AT 12:51:03 ON 19 JAN 2010
L15           1 S US20070259857/PN
                SELECT RN L15 1-

     FILE 'REGISTRY' ENTERED AT 12:51:51 ON 19 JAN 2010
L16          10 S E150-159
L17           1 S L16 AND 5-6-7/SZ

     FILE 'HCAPLUS' ENTERED AT 12:52:13 ON 19 JAN 2010
L18           8 S L13 AND AMORPHOUS

=> d ibib abs hitstr total
```

L18 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1589276 HCAPLUS
DOCUMENT NUMBER: 152:83182
TITLE: Stabilization of amorphous drugs using sponge-like carrier matrixes
INVENTOR(S): Nolte, Marc; Mayer, Joerg; Gonzalez Ferreira, Maria; Assogba-Zandt, Annette; Fehring, Volker; Kroehne, Lutz; Voigt, Andreas; Dunmann, Christoph
PATENT ASSIGNEE(S): Capsulution NanoScience A.-G., Germany
SOURCE: PCT Int. Appl., 30pp.; Chemical Indexing Equivalent to 152:83181 (EP)
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009153346	A2	20091223	WO 2009-EP57688	20090619
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2135601	A1	20091223	EP 2008-158678	20080620
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				

PRIORITY APPLN. INFO.: EP 2008-158678 A 20080620

AB The present invention relates to drug formulations for the stabilization of amorphous forms of drugs. In particular the present invention relates to pharmaceutical compns. comprising sponge-like carrier matrixes, particularly polyelectrolyte complexes or porous particles. The invention also relates to methods for the production of such pharmaceutical compns. Thus, polyelectrolyte complex was produced: solution containing 2% (w/v) protamine sulfate with an ionic strength of 0.01 M was added to a solution containing 2% (w/v) CM-cellulose with an ionic strength of 0.01 M under mixing with an ultra-turrax; the resulting suspension was lyophilized and stored at RT until further use.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilization of amorphous drugs using sponge-like carrier matrixes)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L18 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1589275 HCAPLUS
DOCUMENT NUMBER: 152:83181
TITLE: Stabilization of amorphous drugs using sponge-like carrier matrixes
INVENTOR(S): Gonzalez Ferreiro, Maria; Dunmann, Christoph; Kroehne, Lutz; Voigt, Andreas
PATENT ASSIGNEE(S): Capsulution NanoScience A.-G., Germany
SOURCE: Eur. Pat. Appl., 21pp.; Chemical Indexing Equivalent to 152:83182 (WO)
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 2135601	A1	20091223	EP 2008-158678	20080620
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
WO 2009153346	A2	20091223	WO 2009-EP57688	20090619
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: EP 2008-158678 A 20080620

AB The present invention relates to drug formulations for the stabilization of amorphous forms of drugs. In particular the present invention relates to pharmaceutical compns. comprising sponge-like carrier matrixes, particularly polyelectrolyte complexes or porous particles. The invention also relates to methods for the production of such pharmaceutical compns. Thus, polyelectrolyte complex was produced: solution containing 2% (w/v) protamine sulfate with an ionic strength of 0.01 M was added to a solution containing 2% (w/v) CM-cellulose with an ionic strength of 0.01 M under mixing with an ultra-turrax; the resulting suspension was lyophilized and stored at RT until further use.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilization of amorphous drugs using sponge-like carrier matrixes)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:272342 HCAPLUS
DOCUMENT NUMBER: 149:11956
TITLE: Process for preparation of amorphous olanzapine
AUTHOR(S): Anon.
CORPORATE SOURCE: USA
SOURCE: IP.com Journal (2007), 7(2A), 6 (No. IPCOM000145616D), 19 Jan 2007
CODEN: IJPOBX; ISSN: 1533-0001
PUBLISHER: IP.com, Inc.
DOCUMENT TYPE: Journal; Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IP 145616D		20070119	IP 2007-145616D	20070119

PRIORITY APPLN. INFO.: IP 2007-145616D 20070119

AB Processes for the preparation of amorphous olanzapine which is amenable to com. scale handling have been described. The first process involves (a) treating olanzapine in a suitable solvent, (b) adding a second solvent to the solution from stage (a) or adding solution from stage (a) to a second solvent in order to precipitate olanzapine, and (c) isolating the amorphous olanzapine.
Alternatively, instead of using precipitation by the addition of an antisolvent, amorphous olanzapinepine can also be prepared by a process that involves (a) treating olanzapine with a suitable organic solvent to form a solution, (b) removing the solvent from the reaction mass, and (c) isolating amorphous olanzapine.

IT 132539-06-1P, Olanzapine
RL: PUR (Purification or recovery); PREP (Preparation)
(process for preparation of amorphous olanzapine)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L18 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:638706 HCAPLUS
DOCUMENT NUMBER: 143:159548
TITLE: Donepezil formulations
INVENTOR(S): Boehm, Garth; Dundon, Josephine
PATENT ASSIGNEE(S): Alpharma, Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065645	A2	20050721	WO 2004-US42999	20041223
WO 2005065645	A3	20051027		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2552221	A1	20050721	CA 2004-2552221	20041223
US 20050232990	A1	20051020	US 2004-22346	20041223
EP 1776089	A2	20070425	EP 2004-815115	20041223
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2006DN04397	A	20070713	IN 2006-DN4397	20060728
PRIORITY APPLN. INFO.:			US 2003-533496P P	20031231
			WO 2004-US42999 W	20041223

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB Donepezil formulations, including amorphous donepezil or pharmaceutically acceptable salts thereof; sustained-release formulations; and donepezil sprinkle formulations are disclosed.
IT 132539-06-1, Olanzapine
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(donepezil formulations)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	7	THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT:	8	THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:1154719 HCAPLUS
DOCUMENT NUMBER: 142:79941
TITLE: Novel amorphous form of olanzapine
INVENTOR(S): Gray, Jason
PATENT ASSIGNEE(S): Generics UK Limited, UK
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113346	A1	20041229	WO 2004-GB2579	20040615
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1633757	A1	20060315	EP 2004-736845	20040615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 20070259857	A1	20071108	US 2007-561009	20070621

PRIORITY APPLN. INFO.: GB 2003-14149 A 20030618
WO 2004-GB2579 W 20040615
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to an amorphous form of olanzapine and a process for its preparation The present invention further relates to a pharmaceutical composition comprising an amorphous form of olanzapine. The pharmaceutical composition may be used, in particular, for the treatment of psychiatric, psychol. or psychotic disorders, anxiety disorders, or gastrointestinal or functional bowel disorders. The present invention also relates to a method of treating said disorders.

IT 132539-06-1, Olanzapine
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(oral and parenteral compns. containing amorphous olanzapine and excipients)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:565067 HCAPLUS
DOCUMENT NUMBER: 141:111572
TITLE: High pressure compaction for pharmaceutical formulations
INVENTOR(S): Smith, Thomas J.; Gauzer, Gene
PATENT ASSIGNEE(S): St. James Associates LLC/Faber Research Series, USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058222	A1	20040715	WO 2003-US41392	20031222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2510319	A1	20040715	CA 2003-2510319	20031222
CA 2510320	A1	20040715	CA 2003-2510320	20031222
AU 2003299983	A1	20040722	AU 2003-299983	20031222
EP 1583519	A1	20051012	EP 2003-800248	20031222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006521287	T	20060921	JP 2005-510070	20031222
US 20070218139	A1	20070920	US 2007-538991	20070409

PRIORITY APPLN. INFO.:		
US 2002-435037P	P	20021220
US 2002-435038P	P	20021220
US 2002-435075P	P	20021220
US 2002-435106P	P	20021220
US 2002-435132P	P	20021220
US 2002-435162P	P	20021220
US 2002-435163P	P	20021220
US 2002-435336P	P	20021220
US 2002-435338P	P	20021220
US 2002-435372P	P	20021220
US 2002-435388P	P	20021220
US 2002-435415P	P	20021220
US 2002-435416P	P	20021220
US 2002-435423P	P	20021220
US 2002-435445P	P	20021220
US 2002-435447P	P	20021220
US 2002-435449P	P	20021220
US 2002-435488P	P	20021220
US 2002-435494P	P	20021220
US 2002-435495P	P	20021220
US 2002-435496P	P	20021220
US 2002-435497P	P	20021220

US 2002-435501P	P	20021220
US 2002-435505P	P	20021220
US 2002-435506P	P	20021220
US 2002-435507P	P	20021220
US 2002-435508P	P	20021220
US 2002-435509P	P	20021220
US 2002-435557P	P	20021220
US 2002-435558P	P	20021220
US 2002-435565P	P	20021220
US 2002-435630P	P	20021220
US 2002-435632P	P	20021220
US 2003-450722P	P	20030228
US 2003-454997P	P	20030314
US 2002-435448P	P	20021220
WO 2003-US41392	W	20031222

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods for producing a pharmaceutical preparation of pressure-fused particles including an active pharmaceutical ingredient are disclosed. The methods include the application of a pressure of between 0.1 GPa and 10 GPa to produce a compacted sample. The pressure-fused particles of the invention are useful for parenteral administration, and particularly sustained-release formulations, due to dissoln. kinetics which are superior to conventional crystalline or amorphous packed powder prepns. of active pharmaceutical ingredients. Pharmaceutical prepns. including such pressure-fused microparticles are also disclosed.

IT 132539-06-1, Olanzapine
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pressure-fused particles for parenteral administration)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L18 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:76577 HCAPLUS
DOCUMENT NUMBER: 138:142460
TITLE: 2-Methylthienobenzodiazepine lyophilized formulation
INVENTOR(S): Dekemper, Kurt Douglas; Fites, Alan Lee; Nail, Steven L.
PATENT ASSIGNEE(S): Eli Lilly Company, USA
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003007912	A2	20030130	WO 2002-US19799	20020705
WO 2003007912	A3	20030501		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2448724	A1	20030130	CA 2002-2448724	20020705
AU 2002320134	A1	20030303	AU 2002-320134	20020705
AU 2002320134	B2	20070405		
NZ 529667	A	20031219	NZ 2002-529667	20020705
EP 1423124	A2	20040602	EP 2002-749634	20020705
EP 1423124	B1	20070808		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011250	A	20040727	BR 2002-11250	20020705
CN 1537007	A	20041013	CN 2002-814447	20020705
JP 2004537546	T	20041216	JP 2003-513521	20020705
AT 369137	T	20070815	AT 2002-749634	20020705
PT 1423124	E	20071029	PT 2002-749634	20020705
HU 2004001157	A3	20080128	HU 2004-1157	20020705
ES 2289126	T3	20080201	ES 2002-749634	20020705
US 20040176357	A1	20040909	US 2003-480617	20031210
IN 2004KN00051	A	20060331	IN 2004-KN51	20040115
MX 2004000541	A	20040504	MX 2004-541	20040116
ZA 2004000798	A	20050503	ZA 2004-798	20040130
HK 1066484	A1	20080201	HK 2004-109512	20041201

PRIORITY APPLN. INFO.:	US 2001-306829P	P	20010720
	US 2002-386474P	P	20020607
	WO 2002-US19799	W	20020705

AB The invention provides an amorphous, lyophilized, parenteral formulation of olanzapine. Tartaric acid is used a solubilizer and lactose as stabilizer.

IT 132539-06-1, Olanzapine 491828-16-1
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);

USES (Uses)
(2-methylthienobenzodiazepine lyophilized formulation)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



RN 491828-16-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine,
2-methyl-4-(4-methyl-1-piperazinyl)-, (2R,3R)-2,3-dihydroxybutanedioate
(1:1) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



OS.CITING REF COUNT:	4	THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:754995 HCAPLUS
DOCUMENT NUMBER: 137:268473
TITLE: Porous drug matrices and methods of manufacture thereof
INVENTOR(S): Straub, Julie; Altreuter, David; Bernstein, Howard; Chickering, Donald E.; Khattak, Sarwat; Randall, Greg
PATENT ASSIGNEE(S): Acusphere Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U. S. 6,395,300.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020142050	A1	20021003	US 2002-53929	20020122
US 6395300	B1	20020528	US 1999-433486	19991104
EP 1642572	A1	20060405	EP 2005-27194	20000525
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 6645528	B1	20031111	US 2000-694407	20001023
US 6932983	B1	20050823	US 2000-706045	20001103
ZA 2001010347	A	20030730	ZA 2001-10347	20011218
US 20050048116	A1	20050303	US 2004-924642	20040824
US 20050058710	A1	20050317	US 2004-928886	20040827
PH 1200600163	A	20090824	PH 2006-1200600163	20060322

PRIORITY APPLN. INFO.:		
US 1999-136323P	P	19990527
US 1999-158659P	P	19991008
US 1999-433486	A2	19991104
US 2000-186310P	P	20000302
EP 2000-939365	A3	20000525
PH 2000-1200001402	A3	20000529
US 2002-53929	A3	20020122

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissoln. of the drug in aqueous media. The drug matrixes preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissoln. following administration to a patient, as compared

to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration. Thus, 5.46 g of PEG 8000, 0.545 g of prednisone, and 0.055 g of Span 40 were dissolved in 182 mL of methylene chloride. A solution of 3.27 g of ammonium bicarbonate in 18.2 mL of water was added to the organic solution (phase ratio 1:10) and homogenized for 5 min at 16,000 RPM. The resulting emulsion was spray dried on a benchtop spray dryer using an air-atomizing nozzle and nitrogen as the drying gas.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(porous drug matrixes and methods of manufacture thereof)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

```
=> => d his

     (FILE 'HOME' ENTERED AT 12:08:40 ON 19 JAN 2010)

     FILE 'CAPLUS' ENTERED AT 12:08:51 ON 19 JAN 2010
L1          3420 S OLANZAPINE
L2        705219 S PRECIP?
L3            41 S L1 AND L2
L4             2 S PRECIPTATE/IT
L5         17536 S PRECIPITATE/IT
L6             1 S L1 AND L5

     FILE 'REGISTRY' ENTERED AT 12:10:18 ON 19 JAN 2010
L7             1 S OLANZAPINE/CN
L8             1 S 132539-06-1/RN

     FILE 'REGISTRY' ENTERED AT 12:11:57 ON 19 JAN 2010
L9                STR 132539-06-1
L10          111 S L9 FAM FUL

     FILE 'HCAPLUS' ENTERED AT 12:12:39 ON 19 JAN 2010
L11       144033 S (CRYST?) AND (POLYMORPH? OR POLYTYP? OR POLYSTRUCTUR? OR DIMO

     FILE 'REGISTRY' ENTERED AT 12:13:35 ON 19 JAN 2010
                SELECT CHEM L10 1-
                DEL SEL Y
                SEL CHEM L10
L12             QUE E2-131

     FILE 'HCAPLUS' ENTERED AT 12:17:27 ON 19 JAN 2010
L13         3496 S L12

     FILE 'REGISTRY' ENTERED AT 12:24:43 ON 19 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 12:25:38 ON 19 JAN 2010

     FILE 'REGISTRY' ENTERED AT 12:26:07 ON 19 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 12:27:33 ON 19 JAN 2010
                SELECT RN L30 1-

     FILE 'REGISTRY' ENTERED AT 12:28:11 ON 19 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 12:28:58 ON 19 JAN 2010
                S C17 H20 N4 S/MF

     FILE 'REGISTRY' ENTERED AT 12:29:47 ON 19 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 12:29:47 ON 19 JAN 2010

     FILE 'REGISTRY' ENTERED AT 12:30:18 ON 19 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 12:30:51 ON 19 JAN 2010

     FILE 'REGISTRY' ENTERED AT 12:40:52 ON 19 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 12:41:11 ON 19 JAN 2010
```

```
     FILE 'REGISTRY' ENTERED AT 12:44:43 ON 19 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 12:46:03 ON 19 JAN 2010

     FILE 'REGISTRY' ENTERED AT 12:50:22 ON 19 JAN 2010
L14           0 S L10 AND AMORPHOUS

     FILE 'HCAPLUS' ENTERED AT 12:51:03 ON 19 JAN 2010
L15           1 S US20070259857/PN
                SELECT RN L15 1-

     FILE 'REGISTRY' ENTERED AT 12:51:51 ON 19 JAN 2010
L16          10 S E150-159
L17           1 S L16 AND 5-6-7/SZ

     FILE 'HCAPLUS' ENTERED AT 12:52:13 ON 19 JAN 2010
L18           8 S L13 AND AMORPHOUS
L19      402014 S MELT
L20       23333 S FREEZE-DRYING
L21       16694 S SPRAY DRYING
L22           0 S L18 AND L19
L23           3 S L18 AND L20
L24           1 S L18 AND L21
L25           2 S L13 AND L19
L26          13 S L13 AND L20
L27           6 S L13 AND L21
L28          57 S L13 AND LACTOSE
L29          23 S L13 AND POVIDONE
L30          29 S L13 AND CROSPOVIDONE
L31          95 S L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30
L32          90 S L31 NOT L18
L33          89 S L32 NOT (2010/SO OR 2009/SO OR 2008/SO OR 2007/SO OR 2006/SO

=> d ibib abs hitstr total
```

L33 ANSWER 1 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1435952 HCAPLUS
DOCUMENT NUMBER: 151:537092
TITLE: Modified release tolterodine formulations
INVENTOR(S): Cherukuri, Subraman Rao; Ravella, Venkat N.
PATENT ASSIGNEE(S): Capricorn Pharma, Inc., USA
SOURCE: PCT Int. Appl., 32pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009140557	A2	20091119	WO 2009-US44044	20090514
WO 2009140557	A3	20100107		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 20090311317	A1	20091217	US 2009-466359	20090514

PRIORITY APPLN. INFO.: US 2008-127523P P 20080514

AB Modified or extended release formulations containing tolterodine and associated methods are disclosed and described. Methods for making and administering said modified release formulations are also disclosed.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modified release tolterodine formulations)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L33 ANSWER 2 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1231135 HCAPLUS
DOCUMENT NUMBER: 151:456529
TITLE: Use of a biologically active blood serum for the treatment of a disorder characterized in a reduced function of a GABA receptor
INVENTOR(S): Hanz, Christoph
PATENT ASSIGNEE(S): Switz.
SOURCE: U.S. Pat. Appl. Publ., 26pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20090252786	A1	20091008	US 2009-411509		20090326
PRIORITY APPLN. INFO.:			US 2008-40813P	P	20080331

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to a method of preventing or treating in a subject a disorder characterized in a reduced GABA receptor function by administering to the subject a therapeutically effective amount of a pharmacol. active blood serum product obtainable by a method comprising electrostimulation of a non-human animal, withdrawal of blood from said animal, isolation of serum from said blood, and gamma irradiation of said serum. Pharmaceutical compns. comprise the biol. active blood serum and selected drugs such as GABA receptor agonists. Blood serum was obtained from chickens treated with electroshock. The serum was γ irradiated and lyophilized. The blood serum attenuated discharges in hippocampus slices when they were treated with GABA antagonists such as pentylenetetrazole and bicuculline.

IT 132539-06-1, Olanzapine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition containing biol. active blood serum and; biol. active blood serum for treatment of disorder characterized by reduced function of GABA receptor)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L33 ANSWER 3 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:858874 HCAPLUS
DOCUMENT NUMBER: 151:156441
TITLE: Solid pharmaceutical dosage form comprising drugs in combination with polymers
INVENTOR(S): Lulla, Amar; Malhotra, Geena
PATENT ASSIGNEE(S): Cipla Limited, India; Curtis, Philip, Anthony
SOURCE: PCT Int. Appl., 39pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009087410	A2	20090716	WO 2009-GB83	20090112
WO 2009087410	A3	20090917		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
IN 2008MU00089	A	20091002	IN 2008-MU89	20080111

PRIORITY APPLN. INFO.:
IN 2008-MU89 A 20080111
IN 2008-MU489 A 20080310
IN 2008-MU619 A 20080324

AB A pharmaceutical composition comprising a solid unit dosage form comprising: one or more of pharmaceutically active ingredients selected from valacyclovir, olanzapine, voriconazole, topotecan, artesunate, amodiaquine, guggulosterone, ramipril, telmisartan, tibolone, atorvastatin, simvastatin, amlodipine, ezetimibe, fenofibrate, tacrolimus, valgancyclovir, valsartan, clopidogrel, estradiol, trenbolone, efavirenz, metformin, pseudoephedrine, verapamil, felodipine, valproic acid/sodium valproate, mesalamine, hydrochlorothiazide, levosulpiride, nelfinavir, cefixime and cefpodoxime proxetil in combination with a water insol. polymer and/or a water soluble polymer. Methods for making the pharmaceutical composition are also disclosed. Thus, solid dosage form comprised (in mg/tablet): valgancyclovir hydrochloride 496.30, kollidon VA-64 450.00, sorbitan monolaurate (Span 20) 22.50; Extragranular: microcryst. cellulose 105.20, crospovidone 20.00, magnesium stearate 6.00; Film coating: ready color mix system 15.00, purified water q.s.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid pharmaceutical dosage form comprising drugs in combination with polymers)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 4 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:826274 HCAPLUS
DOCUMENT NUMBER: 151:132233
TITLE: Taste-masked orally disintegrating tablets of memantine hydrochloride
INVENTOR(S): Pilgaonkar, Pratibha S.; Rustomjee, Maharukh T.; Gandhi, Anilkumar S.
PATENT ASSIGNEE(S): Rubicon Research Private Limited, India
SOURCE: PCT Int. Appl., 27pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009084017	A2	20090709	WO 2008-IN660	20081010
WO 2009084017	A3	20090827		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: IN 2007-MU2024 A 20071010

AB The present invention relates to a solid pharmaceutical composition comprising memantine, which dissolves or disintegrates in the oral cavity preferably within about 60 s. The present invention further discloses orally disintegrating tablets of taste-masked memantine of optimal mech. strength comprising memantine along with a taste-masking agent and pharmaceutically acceptable excipients. Memantin-HCl is taste-masked using Eudragit EPO.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(taste-masked orally disintegrating tablets of memantine hydrochloride)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 5 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:703639 HCAPLUS
DOCUMENT NUMBER: 151:16874
TITLE: Oral dispersable tablet
INVENTOR(S): Laich, Tobias; Steenpass, Thomas
PATENT ASSIGNEE(S): Bayer Schering Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 12pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009071219	A2	20090611	WO 2008-EP9968	20081125
WO 2009071219	A3	20090911		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2007-23802 A 20071208

AB The present invention is directed to an oral disintegratable tablet which exhibits oral disintegratability of not more than 60 s. The tablet for oral administration, comprises an effective amount of at least one active agent, an amount of at least 50% (weight/weight) of a water insol. parts, a surfactant and a disintegrant, such that said tablet is orally disintegretable or dispersable.

IT 132539-06-1, Olanzapine
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(orally dispersable tablet)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 6 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:425642 HCAPLUS
DOCUMENT NUMBER: 150:406603
TITLE: Orodispersible tablets comprising calcium silicate, diluent and disintegrant
INVENTOR(S): Ubeda Perez, Carmen; Diez Martin, Ignacio; Pablo Alba, Pablo
PATENT ASSIGNEE(S): Laboratorios Lesvi, S.L., Spain
SOURCE: PCT Int. Appl., 24pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009043844	A2	20090409	WO 2008-EP63068	20080930
WO 2009043844	A3	20090618		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2007-380265 A 20071001
US 2007-977166P P 20071003

AB This invention relates to a an orally disintegrating tablet obtainable by direct compression of a dry powdered mixture comprising up to 15% by weight of calcium silicate, at least 50% of a diluent, a disintegrant agent and an active ingredient. It also relates to a process for preparing the tablets by homogeneous blending the specific excipients in powder form and subsequent direct compression of the mixture Said tablets disintegrate quickly in the cavity of the mouth, in particular in less than 15 s. Thus, tablets were prepared by compression of a mixture containing risperidone 2,00 mg, lactose monohydrate 64.3 mg, Crospovidone 2.50 mg, calcium silicate 7.50 mg, sodium cyclamate 2.00 mg, cherry flavor 0.40 mg, colloidal silica 0.40 mg, and magnesium stearate 0.90 mg (disintegration time 12 s).

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(orodispersible tablets comprising calcium silicate, diluent and disintegrant)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 7 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:139431 HCAPLUS
DOCUMENT NUMBER: 150:199372
TITLE: Soluble pyrone analogs such as flavonoids and cyclodextrins including quercetin derivatives and sulfoalkyl ether cyclodextrins, methods and therapeutic compositions such as analgesics
INVENTOR(S): Lee, Ving; Robbins, Wendye
PATENT ASSIGNEE(S): Limerick BioPharma, Inc., USA
SOURCE: PCT Int. Appl., 137pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009018326	A2	20090205	WO 2008-US71568	20080730
WO 2009018326	A3	20090312		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 20090082400	A1	20090326	US 2008-182979	20080730
PRIORITY APPLN. INFO.:			US 2007-953186P P	20070731
			US 2008-76612P P	20080627

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods and compns. are described that comprise pyrone analogs such as flavonoids and cyclodextrins including quercetin and quercetin derivs. and sulfoalkyl ether cyclodextrins. In some cases the compds. of the invention are administered with a therapeutic agent such as an analgesic. In some cases, treatment with the compns. of the invention can result in the modulation of central nervous system and/or fetal effects of substances. Methods and compns. are described for the modulation of efflux transporter activity to increase the efflux of drugs and other compns. out of a physiol. compartment and into an external environment. In particular, the methods and compns. disclosed herein provide for the increase of efflux transporter activity at blood-brain, blood-CSF and placental-maternal barriers to increase the efflux of drugs and other compns. from physiol. compartments, including central nervous system and fetal compartments. Thus, under an inert atmospheric, 18.7 g of sulfobutyl ether-7-β-cyclodextrin (Captisol) is dissolved in about 50 mL of deionized water; 1.24 g of quercetin (equivalent to about 1 g of anhydrous quercetin) is added with stirring; 12 mL of 1 N sodium hydroxide is added over about 5-10 min; 10.5 mL of hydrochloric acid is then added over 5-10 min at a slow enough rate to avoid precipitation; deionized water is then added to total volume of 100 mL; this procedure results in a

sulfobutylether-7-β-cyclodextrin-quercetin aqueous composition at a concentration of
10 mg/mL (33 mM) in quercetin at a pH of about 7.8; the solution was found to be stable on storage for weeks without precipitation

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soluble pyrone analogs such as flavonoids and cyclodextrins including quercetin derivs. and sulfoalkyl ether cyclodextrins, methods and therapeutic compns. such as analgesics)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L33 ANSWER 8 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:24756 HCAPLUS
DOCUMENT NUMBER: 150:114355
TITLE: Salts of potassium ATP (KATP) channel openers and uses thereof
INVENTOR(S): Cowen, Neil M.; Dukes, Lain
PATENT ASSIGNEE(S): Essentialis, Inc., USA
SOURCE: PCT Int. Appl., 295pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2009006483	A1	20090108	WO 2008-US68936		20080701
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
US 20090062264	A1	20090305	US 2008-166251		20080701
PRIORITY APPLN. INFO.:			US 2007-947628P	P	20070702
			US 2007-949207P	P	20070711
			US 2007-950854P	P	20070719
			US 2007-986251P	P	20071107

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 150:114355
AB The invention provides immediate or prolonged administration of certain salts of KATP channel openers, e.g. diazoxide, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiol., metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods for co-administering the salts with other drugs to treat diseases of humans and animals.
IT 132539-06-1, Olanzapine
RL: PAC (Pharmacological activity); PRPH (Prophetic); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(KATP channel opener salts for therapeutic use, combinations with other agents, and pharmaceutical compns.)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 9 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1548696 HCAPLUS
DOCUMENT NUMBER: 150:64070
TITLE: A rupturing controlled release device comprising a subcoat
INVENTOR(S): Pastini, Ana C.; Faour, Joaquina; Vergez, Juan A.; Ricci, Marcelo A.; Fischbein, Gustavo A.
PATENT ASSIGNEE(S): Osmotica Costa Rica Sociedad Anonima, Costa Rica
SOURCE: PCT Int. Appl., 109pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009000216	A2	20081231	WO 2008-CR3	20080626
WO 2009000216	A3	20090716		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20090004229	A1	20090101	US 2008-146069	20080625
PRIORITY APPLN. INFO.:			US 2007-946845P P	20070628
			US 2007-947081P P	20070629

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rupturing controlled release device for drug delivery)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 10 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1512796 HCAPLUS
DOCUMENT NUMBER: 150:41409
TITLE: Pressure sensitive solid pharmaceutical dosage form
INVENTOR(S): Darmuzey, Olivia; MacLeod, Graeme; Cengic, Dzenana
PATENT ASSIGNEE(S): FMC Corp., USA
SOURCE: U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080311162	A1	20081218	US 2007-803825	20070516
PRIORITY APPLN. INFO.:			US 2007-803825	20070516

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB A solid form comprising at least one film enrobing a compacted fill material comprising a pressure sensitive multiparticulate and at least one cushioning agent, in which the multiparticulate and/or the cushioning agent comprises at least one active material, having low friability and wherein the compacted fill material has a d. of at least 0.5 g/mL based on the total solid volume of the solid form and a tensile strength of less than 0.9 MPa.
IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pressure sensitive solid pharmaceutical dosage form)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



L33 ANSWER 11 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1402474 HCAPLUS
DOCUMENT NUMBER: 150:10869
TITLE: Solid pharmaceutical dosage form
INVENTOR(S): Darmuzey, Olivia; Macleod, Graeme; Cengic, Dzenana; Stokes, Kevin M.
PATENT ASSIGNEE(S): FMC Corporation, USA
SOURCE: PCT Int. Appl., 56pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008140461	A1	20081120	WO 2007-US11768	20070516

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: WO 2007-US11768 20070516

AB A solid form comprising at least one film enrobing a compacted fill material wherein: (1) said compacted fill material comprises at least one active material; (2) said solid form shows a weight loss that is less than 1% during a 30 min USP friability test USP 29 Test Number 1216 (page 3046); (3) said compacted fill material has a d. of at least 0.5 g/mL based on the total solid volume of the solid form and a tensile strength of less than 0.9 MPa; and (4) said compacted fill material is present in said solid form in at least a first zone and a second zone and said active material is present in at least one of said zones.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid pharmaceutical dosage form)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 12 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1399348 HCAPLUS
DOCUMENT NUMBER: 149:582517
TITLE: Solid dosage forms of pharmaceutical carriers
INVENTOR(S): Cengic, Dzenana; Darmuzey, Olivia; Macleod, Graeme
PATENT ASSIGNEE(S): FMC Corporation, USA
SOURCE: PCT Int. Appl., 43pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008140460	A1	20081120	WO 2007-US11762	20070516

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: WO 2007-US11762 20070516

AB A solid form comprising at least one film enrobing a compacted fill material having at least one active material contained in a matrix and having low friability, a d. of at least 0.5 g/mL based on the total solid volume of the solid form and a tensile strength less than 0.9 MPa and which exhibits a controlled release profile for release of the active material. Zero order release may be achieved.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid dosage forms of pharmaceutical carriers)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 13 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1396884 HCAPLUS
DOCUMENT NUMBER: 149:582491
TITLE: Pressure sensitive solid pharmaceutical dosage form
INVENTOR(S): Darmuzey, Olivia; Macleod, Graeme; Cengic, Dzenana
PATENT ASSIGNEE(S): FMC Corporation, USA
SOURCE: PCT Int. Appl., 63pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008140459	A1	20081120	WO 2007-US11707	20070516

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: WO 2007-US11707 20070516

AB A solid form comprising at least one film enrobing a compacted fill material comprising a pressure sensitive multiparticulate and at least one cushioning agent, in which the multiparticulate and/or the cushioning agent comprises at least one active material, having low friability and wherein the compacted fill material has a d. of at least 0.5 g/mL based on the total solid volume of the solid form and a tensile strength of less than 0.9 MPa.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pressure sensitive solid pharmaceutical dosage form)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 14 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1068526 HCAPLUS
DOCUMENT NUMBER: 149:315745
TITLE: Water-dispersible pharmaceutical formulation comprising water-soluble and water-swellable diluents and process for preparing the same
INVENTOR(S): Nagaraju, Nagesh; Soni, Prakash Kumar; Mukherji, Gour
PATENT ASSIGNEE(S): Jubilant Organosys Limited, India
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008104996	A2	20080904	WO 2008-IN111	20080227
WO 2008104996	A3	20081211		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
IN 2007DE00444	A	20080912	IN 2007-DE444	20070228
PRIORITY APPLN. INFO.:			IN 2007-DE444 A	20070228

AB Disclosed herein a water-dispersible compressed tablet and process for preparing the same. The tablet comprises (i) about 0.1 to 50% weight/weight of a pharmaceutically active ingredient, such as lamotrigine or its pharmaceutically acceptable salts, solvates, hydrates or polymorphs, (ii) about 5 to about 50% weight/weight of a water-soluble diluent (s), (iii) about 15 to about 70% weight/weight of a water swellable diluent (s), and (iv) optionally one or more pharmaceutically acceptable adjuvants, wherein the ratio of water-soluble diluent(s) to water swellable diluent(s) is from about 0.6 to about 0.9 and said composition is essentially free of disintegrant, superdisintegrant and swellable clay. Thus, a lamotrigine water-dispersible tablet comprised lamotrigine 25.0, spray dried mannitol 100.0, microcryst. cellulose 163.0, Aspartame 6.0, colloidal silica 2.0, magnesium stearate 3.0, and strawberry flavor 1.0 mg, resp.
IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-dispersible tablets comprising water-soluble and water-swellable diluents)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 15 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1024551 HCAPLUS
DOCUMENT NUMBER: 149:499886
TITLE: Method for preparing rapid-disintegrating formulation for oral administration, and drug packaging machine
INVENTOR(S): Lee, Chang Hyeon; Woo, Jong Su; Lee, Hong Gi; Kim, Gyeong Su; Lim, Ho Taek; Lee, Gi Bung
PATENT ASSIGNEE(S): Hanmi Pharmaceutical Co., Ltd., S. Korea
SOURCE: Repub. Korean Kongkae Taeho Kongbo, 20pp.
CODEN: KRXXA7
DOCUMENT TYPE: Patent
LANGUAGE: Korean
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2008076673	A	20080820	KR 2007-63757	20070627
KR 912351	B1	20090814		
WO 2009002084	A2	20081231	WO 2008-KR3623	20080625
WO 2009002084	A3	20090226		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
KR 2009074716	A	20090707	KR 2009-56483	20090624

PRIORITY APPLN. INFO.: KR 2007-15409 A 20070214
KR 2007-63757 A 20070627

AB The title method comprises: (1) filling a packing material with mixed powder containing pharmaceutically active component and sugar or sugar alc., and (2) heating. The formulation can be disintegrated rapidly in mouth. The preparation process is simple and economical.

IT 132539-06-1, Olanzapine
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for preparing rapid-disintegrating formulation for oral administration, and drug packaging machine)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 16 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:975572 HCAPLUS
DOCUMENT NUMBER: 149:252254
TITLE: A dosage form containing two or more active pharmaceutical ingredients in different physical forms such as powder, granule, pellet, bead or tablet
INVENTOR(S): Blundell, Sandra; Keramidas, Panagiotis; Mooney, Brett Antony; Rutherford, Todd James
PATENT ASSIGNEE(S): Alphapharm Pty Ltd, Australia
SOURCE: PCT Int. Appl., 36pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008095263	A1	20080814	WO 2008-AU169	20080211
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2008213744	A1	20080814	AU 2008-213744	20080211
CA 2677623	A1	20080814	CA 2008-2677623	20080211
EP 2120878	A1	20091125	EP 2008-706056	20080211
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: AU 2007-900682 A 20070209
WO 2008-AU169 W 20080211

AB A dosage form for administration of two or more active pharmaceutical ingredients to a subject, comprising a first pharmaceutical composition comprising a first active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipients in a first phys. form selected from the group consisting of powder, granule, pellet, bead or mini-tablet form, and at least a second pharmaceutical composition comprising a second active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipients in a second phys. form selected from the group consisting of granule, pellet, bead, mini-tablet or tablet form, wherein the composition is characterized in that said first and second phys. forms are selected to be different to minimize interactions between said first and second pharmaceutical compns. and to allow separation of said first and second pharmaceutical compns. for anal. on the basis of size difference. Thus, tablet formulation comprised (in mg): Part A (powder): fluoxetine HCl 27.95, maize starch 10.00, pregelatinized maize starch 85.725, magnesium stearate 1.325; Part B (mini-tablet): olanzapine 6.00, lactose anhydrous 47.15, maize starch 5.00, pregelatinized maize starch 1.25, crospovidone 2.00, magnesium stearate 0.60.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dosage form containing two or more active pharmaceutical ingredients in different phys. forms such as powder, granule, pellet, bead or tablet)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 17 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:590637 HCAPLUS
DOCUMENT NUMBER: 148:523682
TITLE: Layered pharmaceutical formulations for treating obesity-related condition
INVENTOR(S): Mckinney, Anthony; Tollefson, Gary; Weber, Eckard; Soltero, Rick
PATENT ASSIGNEE(S): Orexigen Therapeutics, Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 17pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080113026	A1	20080515	US 2007-937421	20071108
AU 2007319471	A1	20080522	AU 2007-319471	20071108
AU 2007319471	A2	20090702		
CA 2668884	A1	20080522	CA 2007-2668884	20071108
WO 2008060963	A2	20080522	WO 2007-US84177	20071108
WO 2008060963	A3	20080710		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 2089005	A2	20090819	EP 2007-864161	20071108
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
KR 2009094263	A	20090904	KR 2009-711226	20071108
MX 2009004874	A	20090616	MX 2009-4874	20090507
CN 101588795	A	20091125	CN 2007-80049440	20090707
PRIORITY APPLN. INFO.:			US 2006-865157P P	20061109
			WO 2007-US84177 W	20071108

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine. Thus, a sustained-release bupropion tablet formulation contained bupropion HCl 70.0, microcryst. cellulose (Avicel PH 101) 173.3, hydroxypropyl cellulose, (Klucel HXF) 56.7, Cysteine HCl 12.5, and magnesium stearate 2.5 mg, resp. A sustained-release zonisamide tablet formulation contained zonisamide 30, Klucel 110, lactose 55, colloidal silica 2, Cross-

povidone 20, magnesium stearate 6, and microcryst. cellulose 127 mg, resp. A layered tablet formulation comprised a first layer comprising a controlled-release zonisamide and a second layer comprising a controlled-release bupropion. The first layer and the second layer may be separated by an intermediate layer comprising lactose or other suitable fast-dissolving ingredient.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(layered pharmaceutical formulations for administration of two or more active agents for treating obesity-related condition)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L33 ANSWER 18 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:412025 HCAPLUS
DOCUMENT NUMBER: 148:387324
TITLE: Olanzapine pharmaceutical composition comprising anhydrous lactose
INVENTOR(S): Osinga, Niels
PATENT ASSIGNEE(S): Synthon B.V., Neth.
SOURCE: PCT Int. Appl., 19pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008037502	A2	20080403	WO 2007-EP8632	20071001
WO 2008037502	A3	20080522		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20080138409	A1	20080612	US 2007-863795	20070928
PRIORITY APPLN. INFO.:			US 2006-827607P P	20060929

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to an olanzapine pharmaceutical composition, such as a tablet that is made using anhydrous lactose as an excipient. Thus, a composition comprising olanzapine Form I 5.0 mg, Pharmatose DCL22 186.5 mg, Aerosil 200 VV 0.5 mg, Polyplasdone XL 6.0 mg, and magnesium stearate 2.0 mg was blended and compressed into a 200.0 mg tablet.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(olanzapine tablets comprising anhydrous lactose as excipient)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 19 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:349619 HCAPLUS
DOCUMENT NUMBER: 148:315401
TITLE: Compressible resilient self-adhering granules comprising polysaccharide and a binder, and oral dosage formulations prepared therefrom
INVENTOR(S): Cherukuri, S. Rao
PATENT ASSIGNEE(S): Capricom Pharma, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U.S. Ser. No. 715,821.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20080069889	A1	20080320	US 2007-899601		20070905
US 20070212417	A1	20070913	US 2007-715821		20070307
PRIORITY APPLN. INFO.:			US 2006-780304P	P	20060307
			US 2007-715821	A2	20070307

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The present invention provides resilient self-adhering granules which comprise a polysaccharide present in an amount from about 10 wt% to about 90 wt% and a binder having a viscosity from about 5,000 mPa·s to about 250,000 mPa·s present in an amount from about 90 wt% to about 10 wt%, wherein the granule is capable of reversible agglomeration at or below 6,500 kilonewtons/m2. The present invention also provides oral dosage compns. comprising the resilient self-adhering granules and methods for making and using the resilient self-adhering granules. Thus, zinc acetate and zinc gluconate comprising resilient granules were prepared (the combined amount of elemental zinc was approx. 10.5 mg in the final compressed product). The composition had the following ingredients: mono- and diglyceride emulsifiers (Durem 117) 60 mg; Panalite 90 DK (maltitol syrup) 30 mg; polyethylene glycol 3350 40 mg; partially hydrogenated soy bean oil and cotton seed oil (Kaomel) 10 mg; acetylated mono- and diglycerides (Myvacet) 50 mg; maltodextrin (Maltrin M-180) 171 mg; maltitol syrup (Lycasin HDS) 200 mg; methylcellulose (Methocel K100) 5 mg; granulated sugar 285 mg; sweeteners and colorants and flavoring aids (about 35 mg).
IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compressible resilient self-adhering granules comprising polysaccharide and a binder, and oral dosage formulations prepared therefrom)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L33 ANSWER 20 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:223667 HCAPLUS
DOCUMENT NUMBER: 148:246539
TITLE: Pharmaceutical tablets containing a plurality of active segments
INVENTOR(S): Kaplan, Allan S.; Solomon, Lawrence
PATENT ASSIGNEE(S): Accu-Break Technologies, Inc., USA
SOURCE: PCT Int. Appl., 25pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008021875	A2	20080221	WO 2007-US75469	20070808
WO 2008021875	A3	20081211		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 2049089	A2	20090422	EP 2007-840774	20070808
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2010500374	T	20100107	JP 2009-523979	20070808

PRIORITY APPLN. INFO.:			
US 2006-836429P	P	20060808
WO 2007-US75469	W	20070808

AB Described are stable compressed pharmaceutical dosage forms, such as tablets, layered so that incompatible active ingredients can be included in a single dosage form, and such that carry over and intermixing are minimized in the manufacture process. A tablet contained chlorthalidone 6.67, dibasic calcium phosphate 15.31, microcryst. cellulose PH-102 67.06, microcryst. cellulose PH-105 6.67, sodium starch glycolate 4.08, Red or Blue Lake 0.01, and magnesium stearate 0.2%.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical tablets containing plurality of active segments)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 21 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:43561 HCAPLUS
DOCUMENT NUMBER: 148:128291
TITLE: A stable olanzapine formulation with antioxidants
INVENTOR(S): Farshi, Farhad
PATENT ASSIGNEE(S): Bilim Ilac Sanayii Ve Ticaret A.S., Turk.
SOURCE: PCT Int. Appl., 9 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008004033	A1	20080110	WO 2006-IB52258	20060705
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2043612	A1	20090408	EP 2006-766006	20060705
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
CN 101484141	A	20090715	CN 2006-80055231	20090105
PRIORITY APPLN. INFO.:			WO 2006-IB52258 W	20060705

AB This invention is related to a stable Olanzapine formulation with antioxidants without subcoating. The antioxidant used in formulation is Bu hydroxyanisole. The stable olanzapine formulation does not need subcoating through using of antioxidant. Coating material is preferably polyvinylalc. based coating material which is preferably Opadry AMB.

IT 132539-06-1, Olanzapine
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(stable olanzapine formulation with antioxidants)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 22 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:12247 HCAPLUS
DOCUMENT NUMBER: 148:106232
TITLE: Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
INVENTOR(S): Singh, Nikhilesh N.
PATENT ASSIGNEE(S): Transcept Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080004260	A1	20080103	US 2007-824201	20070628
WO 2008005345	A2	20080110	WO 2007-US15155	20070629
WO 2008005345	A3	20080320		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20080004291	A1	20080103	US 2007-780442	20070719

PRIORITY APPLN. INFO.: US 2006-817666P P 20060629
US 2007-824201 A 20070628
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The present invention provides novel compns. comprising a combination of a 5-HT3 receptor antagonist and a selective dopamine D2 receptor antagonist for the treatment of alc. dependence and other dopamine pathway-associated disorders or conditions. Preferably, the pharmaceutical compns. of the present invention comprise amts. of the 5-HT3 receptor antagonist ondansetron and the selective dopamine D2 receptor antagonist olanzapine that are sufficient to control a subject's craving for alc. or other addictive substances. Kits comprising the combination of antagonists for the treatment of addictive disorders such as alc. dependence are also provided. Thus, immediate release tablet was prepared containing olanzapine 2.01%, lactose 82%, microcryst. cellulose 10%, hydroxypropyl methylcellulose 2.15, sodium CM-cellulose 3.2%, and magnesium stearate 0.6%.
IT 132539-06-1, Olanzapine
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 23 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:10304 HCAPLUS
DOCUMENT NUMBER: 148:106203
TITLE: Methods for the preparation of biologically active compounds in nanoparticulate form
INVENTOR(S): Meiser, Felix; Cammarano, Raffaele; Caruso, Frank; Postma, Almar
PATENT ASSIGNEE(S): Iceutica Pty Ltd, Australia
SOURCE: PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008000042	A1	20080103	WO 2007-AU910	20070629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2007264418	A1	20080103	AU 2007-264418	20070629
CA 2653384	A1	20080103	CA 2007-2653384	20070629
EP 2054042	A1	20090506	EP 2007-719147	20070629
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009541362	T	20091126	JP 2009-516825	20070629
CN 101568330	A	20091028	CN 2007-80024802	20081230
IN 2009MN00020	A	20090410	IN 2009-MN20	20090102
PRIORITY APPLN. INFO.:			AU 2006-903527 A	20060630
			US 2007-915955P P	20070504
			WO 2007-AU910 W	20070629

AB A composition comprising nanoparticles of a biol. active compound is produced by
dry milling a solid biol. active compound and a millable grinding compound in a mill comprising a plurality of milling bodies, for a time period sufficient to produce a solid dispersion comprising nanoparticles of the biol. active compound dispersed in an at least partially milled grinding compound Thus, a mixture of a biol. active compound (0.439 g of diclofenac acid) and grinding compound (3.681 g of sodium chloride) was dry milled for 15 min. Ultrafine particles of diclofenac acid in nanoparticulate form were recovered by removing the grinding compound through washing with dilute hydrochloric acid and drying.
IT 132539-06-1, Olanzapine
RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(preparation of nanoparticles of biol. active compds. by dry milling with

grinding agents)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 24 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1336663 HCAPLUS
DOCUMENT NUMBER: 148:17639
TITLE: Zero-order modified release solid dosage forms containing hydrophobic polymers and hydrophilic coatings
INVENTOR(S): Rastogi, Suneel Kumar; Meadows, Justin Clark; Gupta, Vishal Kumar
PATENT ASSIGNEE(S): Mallinckrodt Inc., USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007133583	A2	20071122	WO 2007-US11186	20070509
WO 2007133583	A3	20080522		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2007249947	A1	20071122	AU 2007-249947	20070509
CA 2651798	A1	20071122	CA 2007-2651798	20070509
EP 2020995	A2	20090211	EP 2007-776913	20070509
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009536654	T	20091015	JP 2009-509831	20070509
MX 2008014059	A	20081114	MX 2008-14059	20081103
IN 2008CN06059	A	20090327	IN 2008-CN6059	20081107
US 20090110728	A1	20090430	US 2008-299944	20081107
CN 101437494	A	20090520	CN 2007-80016545	20081107

PRIORITY APPLN. INFO.:	US 2006-798889P	P	20060509
	US 2006-856226P	P	20061101
	WO 2007-US11186	W	20070509

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The invention comprises a solid dosage form for delivery of water soluble pharmaceutical agents. The solid dosage form comprises a matrix core containing the pharmaceutical agent and a hydrophobic material, and a coating containing a hydrophilic pore-forming agent and a hydrophobic polymer. The dosage form exhibits a zero-order release profile upon dissoln. For example, coated tablets contained methylphenidate hydrochloride, Klucel HXF, Aqualon T10EC, Prosolv HD90, magnesium stearate, and coatings of Surelease and Opadry.
IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(zero-order modified release solid dosage forms containing hydrophobic polymers and hydrophilic coatings)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L33 ANSWER 25 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1312460 HCAPLUS
DOCUMENT NUMBER: 148:523325
TITLE: Process for the preparation of Form I of Olanzapine
AUTHOR(S): Anon.
CORPORATE SOURCE: USA
SOURCE: IP.com Journal (2007), 7(10B), 6 (No. IPCOM000158856D), 2 Oct 2007
CODEN: IJPOBX; ISSN: 1533-0001
PUBLISHER: IP.com, Inc.
DOCUMENT TYPE: Journal; Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IP 158856D		20071002	IP 2007-158856D	20071002

PRIORITY APPLN. INFO.: IP 2007-158856D 20071002

AB Processes for obtaining substantially pure Olanzapine Form I by spray drying technique and the preparation of substantially pure Olanzapine Form I by crystallization are disclosed.

IT 132539-06-1, Olanzapine
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(preparation of form I of olanzapine by spray drying and crystallization)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L33 ANSWER 26 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1165872 HCAPLUS
DOCUMENT NUMBER: 147:433646
TITLE: Rapidly disintegrable tablets
INVENTOR(S): Grimshaw, Michael N.; Barbieri, Donald J.; Vizzini, Louise M.; Marsh, Steve F.
PATENT ASSIGNEE(S): KV Pharmaceutical Company, USA
SOURCE: U.S., 12pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 7282217	B1	20071016	US 2004-929856		20040830
US 7425341	B1	20080916	US 2007-853355		20070911
PRIORITY APPLN. INFO.:			US 2003-498948P	P	20030829
			US 2004-929856	A3	20040830

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention provides a rapidly disintegrating tablet comprising an active ingredient, a water-soluble, directly compressible carbohydrate, and a water-soluble, directly compressible filler. Also provided is a method of producing a rapidly disintegrating tablet, which method comprises wet granulating a mixture comprising a directly compressible, water soluble carbohydrate, a directly compressible, water insol. filler, a beneficial ingredient, and a solvent, and compressing the granulate to produce the tablet.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rapidly disintegrable tablets)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 216 THERE ARE 216 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 27 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1146801 HCAPLUS
DOCUMENT NUMBER: 147:433622
TITLE: Orally disintegrating tablets
INVENTOR(S): Pilgaonkar, Pratibha S.; Rustomjee, Maharukh T.; Gandhi, Anilkumar S.; Bagde, Pradnya; Morvekar, Hetal N.
PATENT ASSIGNEE(S): Rubicon Research Private Limited, India
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007113856	A2	20071011	WO 2007-IN138	20070330
WO 2007113856	A3	20080605		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2007232098	A1	20071011	AU 2007-232098	20070330
CA 2650498	A1	20071011	CA 2007-2650498	20070330
EP 2001450	A2	20081217	EP 2007-790075	20070330
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009532343	T	20090910	JP 2009-502338	20070330
US 20090208576	A1	20090820	US 2008-293857	20080922
MX 2008012299	A	20081118	MX 2008-12299	20080925
KR 2009008307	A	20090121	KR 2008-726671	20081030
NO 2008004612	A	20081031	NO 2008-4612	20081031
US 20090087485	A1	20090402	US 2008-270905	20081114
CN 101460150	A	20090617	CN 2007-80020160	20081201

PRIORITY APPLN. INFO.:
IN 2006-MU498 A 20060331
WO 2007-IN138 W 20070330
US 2008-293857 A2 20080922

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention describes a directly compressible composite prepared by co-processing a water-soluble excipient and calcium silicate. The present invention further describes the incorporation of the co-processed composite into a tablet formulation. The orally disintegrating tablets are of optimal mech. strength and disintegrate within 60 s in the oral cavity.

IT 132539-06-1, Olanzapine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(orally disintegrating tablets)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L33 ANSWER 28 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1115259 HCAPLUS
DOCUMENT NUMBER: 147:433588
TITLE: Sustained release pharmaceutical composition on the basis of a release system comprising an acid-soluble polymer and a ph-dependent polymer.
INVENTOR(S): Jain, Rajesh; Jindal, Kour Chand; Devarajan, Sampath Kumar
PATENT ASSIGNEE(S): Panacea Biotec Ltd, India
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007110878	A1	20071004	WO 2007-IN110	20070319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
IN 2006DE00832	A	20071005	IN 2006-DE832	20060327
AU 2007230549	A1	20071004	AU 2007-230549	20070319
CA 2647421	A1	20071004	CA 2007-2647421	20070319
EP 2004150	A1	20081224	EP 2007-736570	20070319
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009531420	T	20090903	JP 2009-502333	20070319
MX 2008012486	A	20081010	MX 2008-12486	20080926
CN 101410096	A	20090415	CN 2007-80011425	20080927

PRIORITY APPLN. INFO.: IN 2006-DE832 A 20060327
WO 2007-IN110 W 20070319

AB This invention relates to sustained release pharmaceutical composition comprising at least one poorly soluble active agent(s), at least one solubilizer, a release rate controlling polymer system consisting of an acid-soluble polymer and a pH-dependent polymer, and optionally other pharmaceutically acceptable excipients. The present invention also describes a process for preparation of such compns. and method of using such compns. The sustained release compns. are useful in providing therapeutically effective levels of active agent(s) for extended periods of time. Thus, tablet was prepared containing ziprasidone hydrochloride 46.39 mg, Gelucire 50/13 45.0 mg, anhydrous lactose 12.0 mg, chitosan 187.11 mg, Hypromellose 2208 71.50 mg, polyvinylpyrrolidone 30.0 mg, dichloromethane as needed and magnesium stearate 8.0 mg.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sustained release pharmaceutical composition on basis of a release system comprising an acid-soluble polymer and a ph-dependent polymer)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 29 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1096869 HCAPLUS
DOCUMENT NUMBER: 147:350746
TITLE: Use of olanzapine for the preparation of pharmaceutical compositions treating insomnia
INVENTOR(S): Tran, Pierre V.
PATENT ASSIGNEE(S): USA
SOURCE: Hung. Pat. Appl., 22pp.
CODEN: HUXXCV
DOCUMENT TYPE: Patent
LANGUAGE: Hungarian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
HU 9902882	A2	20000228	HU 1999-2882	19970307
HU 9902882	A3	20000428		
PRIORITY APPLN. INFO.:			HU 1999-2882	19970307

AB The subject of the invention is the olanzapine, or the application of the pharmaceutically suitable salt of this compound for the preparation of pharmaceutical compns. for the treatment of insomnia. According to the invention, preferably, the olanzapine polymorph of form is used. X-ray powder diffraction data are presented. Thus 270 g tech. grade olanzapine was dissolved in 2.7 L ethylacetate; heated, cooled and the product was filtered in vacuum. The obtained olanzapine was formulated to tablets that contained (weight/weight%): hydroxypropyl cellulose 4.0; olanzapine 1.18; lactose 79.32; povidone 5; cellulose 10; magnesium stearate 0.5. Tablets were coated with a mixture of hydroxypropyl cellulose, polyethylene and titania; coated tablets were treated with carnauba wax for printing the identification code.

IT 132539-06-1, Olanzapine 132539-06-1D, Olanzapine, salts
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of olanzapine for preparation of pharmaceutical compns. treating insomnia)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



L33 ANSWER 30 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1092492 HCAPLUS
DOCUMENT NUMBER: 147:392459
TITLE: Taste masked pharmaceutical composition comprising water insol. polymer for oral solid dosage form and process for preparing the same
INVENTOR(S): Kashid, Namdev; Chouhan, Pradeep; Mukherji, Gour
PATENT ASSIGNEE(S): Jubilant Organosys Limited, India
SOURCE: PCT Int. Appl., 27pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007108010	A2	20070927	WO 2007-IN109	20070319
WO 2007108010	A3	20080522		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
IN 2006DE00752	A	20070928	IN 2006-DE752	20060321
PRIORITY APPLN. INFO.:			IN 2006-DE752 A	20060321

AB This invention relates to taste masked pharmaceutical composition suitable for oral solid dosage form comprising adsorbate of unpleasant or objectionable tasting active pharmaceutical agents and water insol. polymer, wherein said active is first blended with adsorbent to achieve partially or significantly taste masking of said active and further granulated the resultant blend with water insol. polymer to strengthen the taste masking without affecting the release of said active. Thus, composition was prepared containing intragranular comprising loperamide hydrochloride 2 mg, magnesium aluminum silicate 14 mg, colloidal silicone dioxide 5 mg, aspartame 3 mg, sodium lauryl sulfate 1 mg, L-hydroxypropyl cellulose 20 mg, polyvinylpyrrolidone K30 3 mg, Eudragit EPO 20 mg, talc 1 mg, acesulfame potassium 4 mg, iso-Pr alc., acetone and water as needed; extragranular comprising Aerosil 200 0.5 mg, sodium stearyl fumarate 0.5 mg, sodium chloride 3 mg, L-hydroxypropylcellulose 5 mg, mannitol 36.4 mg, peppermint flavor 0.8 mg, and strawberry flavor 1.2 mg.
IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(taste masked pharmaceutical composition comprising water insol. polymer for oral solid dosage form and process for preparing same)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L33 ANSWER 31 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1029262 HCAPLUS
DOCUMENT NUMBER: 147:427372
TITLE: Method for preparation of Olanzapine crystal form I
INVENTOR(S): Wang, Peng; Gan, Lixin
PATENT ASSIGNEE(S): Zhejiang Huahai Pharmaceutical Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 12pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101033232	A	20070912	CN 2007-10067892	20070330

PRIORITY APPLN. INFO.: CN 2007-10067892 20070330

AB Olanzapine crystal form I was prepared from crude Olanzapine, dissolving in organic solvent and decoloring with active carbon to obtain high purity Olanzapine (HPLC greater than 99.5%), after that redissolving in methylene chloride, filtering, and spray-drying to get solid crystal. The organic solvent is C1-7 alc., C3-7 ketone, C3-7 ester, or C3-7 ether, or mixed solvent of chloroform, acetonitrile, and two or more of the above solvents in a random ratio. The X-ray powder diffraction spectrum of Olanzapine crystal form I under Cu-Ka radiation and IR absorption spectrum measured by KBr pressed disk method are characterized. The method has the advantages of high yield (greater than 90%), high product purity, and low cost.

IT 132539-06-1P, Olanzapine
RL: PRP (Properties); PUR (Purification or recovery); PREP (Preparation)
(preparation of Olanzapine crystal form I)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L33 ANSWER 32 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1016569 HCAPLUS
DOCUMENT NUMBER: 148:503081
TITLE: Novel drug delivery system
INVENTOR(S): Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh Singh; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India
SOURCE: Indian Pat. Appl., 80pp., Addn. of Indian Appl. No. 2004MU198.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2005MU01012	A	20070831	IN 2005-MU1012	20050826
PRIORITY APPLN. INFO.:			IN 2004-MU198 A0	20040220

AB A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise addnl. another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.
IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel drug delivery system)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L33 ANSWER 33 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:993749 HCAPLUS
DOCUMENT NUMBER: 147:330433
TITLE: Composition and method for topical treatment of tar-responsive dermatological disorders
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.; Lee, Yaling
PATENT ASSIGNEE(S): Tristrata, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 15pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070207222	A1	20070906	US 2007-680227	20070228
AU 2007223560	A1	20070913	AU 2007-223560	20070228
AU 2007223560	A2	20081016		
CA 2644311	A1	20070913	CA 2007-2644311	20070228
WO 2007103687	A2	20070913	WO 2007-US62975	20070228
WO 2007103687	A3	20081211		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1998788	A2	20081210	EP 2007-757636	20070228
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009528382	T	20090806	JP 2008-557487	20070228
MX 2008011236	A	20090210	MX 2008-11236	20080902
CN 101460060	A	20090617	CN 2007-80015758	20081031

PRIORITY APPLN. INFO.:	US 2006-778128P	P	20060301
	WO 2007-US62975	W	20070228

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to a composition including a wax and a therapeutically effective amount of tar for topical treatment of a tar-responsive dermatol. disorder, the composition being in liquid or light gel form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal. The invention also relates to a method of treating a tar-responsive dermatol. disorder by topically applying the composition to skin of a mammal, preferably a human, that is affected by the disorder. Thus, a fast-drying liquid tar composition was formulated containing coal tar solution 15 g, ethanol 42 g, propylene glycol 5 g, cyclomethicone (DC 345) 15 g, tri-Et citrate 5 g, Brij 93 10 g, liquid wax DIADD (dioctyldodecyl dodecanedioate) 5 g, and an optional

fragrance 3 g. Topical application of the composition for 4 mo to a human subject having plaque psoriasis resulted in 90% improvement of clin. signs of disorder.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(composition and method for topical treatment of tar-responsive dermatol. disorders)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L33 ANSWER 34 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:907658 HCAPLUS
DOCUMENT NUMBER: 147:263388
TITLE: Water soluble protein hydrolyzate excipients for effective drug delivery formulations
INVENTOR(S): Mark, William Antonio; Hall, Lloyd Thomas
PATENT ASSIGNEE(S): Wyeth, USA
SOURCE: U.S. Pat. Appl. Publ., 18 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070190130	A1	20070816	US 2006-354974	20060216
WO 2007097936	A2	20070830	WO 2007-US3662	20070213
WO 2007097936	A3	20071115		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1986614	A2	20081105	EP 2007-750494	20070213
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.: US 2006-354974 A 20060216
WO 2007-US3662 W 20070213
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB A pharmaceutical composition comprising an effective amount of a pharmaceutical active and up to about 99.8% wt/wt water-soluble protein hydrolyzate to total weight of composition is provided. Whey protein hydrolyzate is exemplary of a suitable soluble protein hydrolyzate. A method for preparing such a composition is also provided. Thus, tablets formed by direct compression comprised 200 mg ibuprofen, 25 mg Biozate, 8 mg Aerosil, 80 mg starch, 6.7 mg Crospovidone, 17.5 mg Croscarmellose sodium, 20 mg sodium starch glycolate, 50 mg Avicel and 3 mg stearic acid. The tablets dissolved considerably faster than tablets lacking the protein hydrolyzate.
IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-soluble protein hydrolyzate excipients)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 35 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:769872 HCAPLUS
DOCUMENT NUMBER: 148:387155
TITLE: Novel dosage form
INVENTOR(S): Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh Singh; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India
SOURCE: Indian Pat. Appl., 96pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2005MU01013	A	20070629	IN 2005-MU1013	20050826
PRIORITY APPLN. INFO.:			IN 2005-MU1013	20050826

AB A dosage form comprising of a high-dose, high-solubility active ingredient for modified release and a low-dose active ingredient for immediate release wherein the weight ratio of immediate-release active ingredient and modified-release active ingredient is from 1:10 to 1:15000 and the weight of modified-release active ingredient per unit is from 500 mg to 1500 mg. A process for preparing the dosage form is provided.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form containing modified-release and immediate-release active ingredients)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L33 ANSWER 36 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:763639 HCAPLUS
DOCUMENT NUMBER: 147:173626
TITLE: Pharmaceutical compositions containing N-(phosphonoalkyl)-amino acids
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 23pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070161543	A1	20070712	US 2007-621287	20070109
US 7429575	B2	20080930		
AU 2007204755	A1	20070719	AU 2007-204755	20070109
CA 2637027	A1	20070719	CA 2007-2637027	20070109
WO 2007082206	A2	20070719	WO 2007-US60273	20070109
WO 2007082206	A3	20071213		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1979366	A2	20081015	EP 2007-717264	20070109
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009526755	T	20090723	JP 2008-550479	20070109
US 20080306025	A1	20081211	US 2008-194203	20080819
US 7572776	B2	20090811		
CN 101395164	A	20090325	CN 2007-80007801	20080904
US 20090208499	A1	20090820	US 2009-428906	20090423

PRIORITY APPLN. INFO.:

US 2006-757614P	P	20060110
US 2007-621287	A3	20070109
WO 2007-US60273	W	20070109
US 2008-194203	A3	20080819

OTHER SOURCE(S): MARPAT 147:173626

AB The present invention relates to an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof, the N-(phosphonoalkyl)-amino acid, related compound or derivative thereof being in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, other than N-(phosphonomethyl)glycine or N,N-bis(phosphonomethyl)glycine. Also included is a composition including an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, and a cosmetically or pharmaceutically acceptable vehicle for topical or systemic administration

to a mammalian subject, as well as a method of administering an effective amount of such a composition for alleviating or improving a condition, disorder, symptom or syndrome associated with at least one of a nervous, vascular, musculoskeletal or cutaneous system. N-(phosphonomethyl)creatinine and propylene glycol were used in the preparation of a topical composition

IT 132539-06-1, Olanzapine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing N-(phosphonoalkyl)-amino acids)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	28	THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 37 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:728826 HCAPLUS
DOCUMENT NUMBER: 147:125589
TITLE: Oral formulation of anhydrous olanzapine form I
INVENTOR(S): Diez Martin, Ignacio; Ubeda Perez, Carmen; Pablo Alba, Pablo
PATENT ASSIGNEE(S): Laboratorios Lesvi, S.L., Spain
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007074110	A1	20070705	WO 2006-EP69905	20061219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
ES 2279715	A1	20070816	ES 2005-3183	20051226
ES 2279715	B1	20080601		
EP 1965773	A1	20080910	EP 2006-841451	20061219
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009521518	T	20090604	JP 2008-547947	20061219
US 20080311203	A1	20081218	US 2008-159030	20080624
KR 2008080230	A	20080902	KR 2008-718344	20080725

PRIORITY APPLN. INFO.:			
ES 2005-3183	A	20051226	
US 2005-754104P	P	20051227	
WO 2006-EP69905	W	20061219	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The invention relates to a solid formulation for the oral administration of olanzapine that comprises a core of anhydrous olanzapine Form I or a pharmaceutically acceptable salt thereof and, optionally, pharmaceutically acceptable excipients, said core being coated with a functional polymer that acts as film-forming agent. The method for obtaining it comprises: i) providing anhydrous olanzapine Form I or a salt thereof and, optionally, pharmaceutically acceptable excipients in solid form; ii) providing a functional polymer that acts as film former; iii) preparing a dispersion of said functional polymer in an aqueous medium,- and
applying the dispersion obtained in step iii) onto the solid form of step i) . A composition contains olanzapine form I, lactose monohydrate, microcryst. cellulose, low-substituted, hydropropyl cellulose, Crospovidone, anhydrous colloidal silica, and Mg

stearate.

IT 132539-06-1, Olanzapine
RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(oral formulation of anhydrous olanzapine form I)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 38 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:728812 HCAPLUS
DOCUMENT NUMBER: 147:125588
TITLE: Mouth dissolving pharmaceutical composition and process for preparing the same
INVENTOR(S): Kashid, Namdev; Mukherji, Gour
PATENT ASSIGNEE(S): Jubilant Organosys Limited, India
SOURCE: PCT Int. Appl., 25pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007074472	A2	20070705	WO 2006-IN319	20060830
WO 2007074472	A3	20070816		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
IN 2005DE03482	A	20091002	IN 2005-DE3482	20051227
EP 1978939	A2	20081015	EP 2006-796197	20060830
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009521523	T	20090604	JP 2008-548082	20060830
US 20080317853	A1	20081225	US 2008-97813	20080617
PRIORITY APPLN. INFO.:			IN 2005-DE3482 A	20051227
			WO 2006-IN319 W	20060830

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Disclosed herein is an orally disintegrating and/or dissolving oral pharmaceutical composition, comprising one or more active pharmaceutical ingredients, one or more fillers having particle size of 100 μ or above, a high and desirable amount of SiO2, one or more disintegrating agents, optionally effervescent couple, wherein said composition has good organoleptic properties like desired mouth feel and fast oral disintegration time.

IT 132539-06-1, Olanzapine
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(oral pharmaceutical composition dissolving in mouth)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 39 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:536945 HCAPLUS
DOCUMENT NUMBER: 146:507832
TITLE: Multi-stage process to control particle size of pharmaceutical substance
INVENTOR(S): Mooney, Brett Antony
PATENT ASSIGNEE(S): Alphapharm Pty. Ltd., Australia; Keramidas, Panagiotis
SOURCE: PCT Int. Appl., 27pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2007053904	A1	20070518	WO 2006-AU1687		20061110
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
AU 2006313009	A1	20070518	AU 2006-313009		20061110
CA 2628716	A1	20070518	CA 2006-2628716		20061110
EP 1951197	A1	20080806	EP 2006-804507		20061110
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS					
US 20090220609	A1	20090903	US 2008-93045		20080808
PRIORITY APPLN. INFO.:			AU 2005-906227	A	20051110
			WO 2006-AU1687	W	20061110

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB This invention relates to multi-stage process to control the particle size of a pharmaceutical substance comprising the steps of: passing the pharmaceutical substance through a first stage of a particle size reduction process with a first set of particle size control parameters to obtain a feedstock of reduced median particle size and lesser distribution of median particle size for a second stage of a particle size reduction process; passing the feedstock, through a second stage of a particle size reduction process with a second set of particle size control parameters; optionally, using the product of the second stage or subsequent stages as a feedstock in further stages of a multi-stage particle size reduction process with a set of particle size control parameters for each stage; and collecting a pharmaceutical substance with a median particle size greater than 10μm and with a narrow, reproducible distribution of median particle sizes. Thus, oxcarbazepine was milled in a 12" spiral jet mill to produce particle size of 15μm to 17μm.

IT 132539-06-1, Olanzapine
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(multi-stage process to control particle size of pharmaceutical substance)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 40 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:512091 HCAPLUS
DOCUMENT NUMBER: 146:468643
TITLE: A pharmaceutical formulation containing olanzapine
INVENTOR(S): Kristjansson, Torfi
PATENT ASSIGNEE(S): Actavis Group PTC EHF, Iceland
SOURCE: PCT Int. Appl., 7 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007052164	A2	20070510	WO 2006-IB3922	20061027
WO 2007052164	A3	20070809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
CA 2626585	A1	20070510	CA 2006-2626585	20061027
EP 1928428	A2	20080611	EP 2006-831860	20061027
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
DE 202006020223	U1	20080612	DE 2006-202006020223	20061027
CN 101309673	A	20081119	CN 2006-80040948	20080430
US 20090035332	A1	20090205	US 2008-91877	20080915
PRIORITY APPLN. INFO.:			GB 2005-22473 A	20051103
			GB 2005-22474 A	20051103
			WO 2006-IB3922 W	20061027

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB This invention relates to a stable pharmaceutical formulation containing olanzapine. The composition comprises olanzapine or a salt thereof, and 1 or more suitable pharmaceutical excipients, wherein the composition is coated with a coating comprising polyvinyl alc. A coating formulation contained polyvinyl alc. 45.52, talc 20.00, TiO2 32.00, xanthan gun 0.48, and soya lecithin 2.00%. Tablets containing olanzapine were coated with the above formulation.
IT 132539-06-1, Olanzapine
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulations containing olanzapine)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 41 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:512090 HCAPLUS
DOCUMENT NUMBER: 146:468642
TITLE: A pharmaceutical formulation containing olanzapine
INVENTOR(S): Stefansson, Stefan Einar
PATENT ASSIGNEE(S): Actavis Group PTC EHF, Iceland
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007052167	A2	20070510	WO 2006-IB3937	20061027
WO 2007052167	A3	20080313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
CA 2626586	A1	20070510	CA 2006-2626586	20061027
DE 202006020224	U1	20080619	DE 2006-202006020224	20061027
EP 1951205	A2	20080806	EP 2006-842365	20061027
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
CN 101309671	A	20081119	CN 2006-80040957	20080430
US 20090221560	A1	20090903	US 2008-92033	20081020
PRIORITY APPLN. INFO.:			GB 2005-22473 A	20051103
			WO 2006-IB3937 W	20061027

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB This invention relates to a stable pharmaceutical formulation containing olanzapine. The composition comprises olanzapine or a salt thereof, a suitable pharmaceutical excipient and a benzodiazepin-4-ylpiperazinium derivative (I). Thus, tablet contained olanzapine 2.5 (containing I ate 0.05% olanzapine), Compactrol 68.5, microcryst. cellulose 25.0, Crospovidone 3.0, and Mg stearate 1.0 mg/tablet.
IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulations containing olanzapine)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 42 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:485162 HCAPLUS
DOCUMENT NUMBER: 146:468578
TITLE: Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
INVENTOR(S): Mehta, Pavak; Gupta, Piyush; Bhaskar, Rajesh
PATENT ASSIGNEE(S): Jubilant Organosys Limited, India
SOURCE: PCT Int. Appl., 19pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007049304	A2	20070503	WO 2006-IN430	20061027
WO 2007049304	A3	20070726		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
IN 2005DE02880	A	20091002	IN 2005-DE2880	20051027
PRIORITY APPLN. INFO.:			IN 2005-DE2880 A	20051027

AB Disclosed herein are stable solid coated oral formulations of olanzapine and the process of preparation thereof. The formulation comprises effective amount of olanazpine and pharmaceutically acceptable excipient, wherein said formulation is coated with stabilized coating employing a selective polymer selected from hydroxypropyl Me cellulose phthalate, polyvinyl acetate phthalate, cellulose acetate phthalate, hydroxypropyl Me cellulose acetate succinate, polyvinyl alc., vinyl acetate copolymer, pullulan gum or zein or in combination thereof. Thus, core tablets were prepared containing olanazpine 10 mg, lactose monohydrate 272 mg, hydroxypropyl cellulose 16 mg, crospovidone 40 mg, microcryst. cellulose 60 mg, and magnesium stearate 2 mg. Core tablets were then coated with a composition containing hydroxypropyl Me cellulose phthalate 3.0 mg, NaOH 1.2 mg, lactose 3.6 mg, triacetin 1.8 mg, talc 1.2 mg, titanium dioxide 1.2 mg and water as needed. Coated tablets were stable for one month at 40°/75% relative humidity in open air.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polymer-coated stable solid oral formulations of olanzapine)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 43 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:391246 HCAPLUS
DOCUMENT NUMBER: 147:508590
TITLE: Gastroretentive inlay tablets for low dose active ingredient
INVENTOR(S): Nadkarni, Sunil Sadanand
PATENT ASSIGNEE(S): India
SOURCE: Indian Pat. Appl., 84pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2004MU01360	A	20060721	IN 2004-MU1360	20041220

PRIORITY APPLN. INFO.: IN 2004-MU1360 20041220

AB The present invention relates to modified release dosage form for low dose active ingredient targeted to be delivered in the proximal part of the gastrointestinal tract and preparation thereof. The dosage form of the present invention is an inlay tablet comprising of two ingredient is embedded in the outer portion comprising an active ingredient is embedded in the outer portion. The inner portion of the said dosage form comprises of pharmaceutically active ingredient, release controlling agent(s) and pharmaceutically acceptable excipients and the outer portion comprises one or more hydrophobic non-biodegradable materials, one or more water soluble diluent(s) and other pharmaceutically acceptable excipients. The dosage form mad by using the present invention is gastro retentive.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gastroretentive inlay tablets for low dose active ingredient)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L33 ANSWER 44 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:385013 HCAPLUS
DOCUMENT NUMBER: 146:387123
TITLE: Microparticles with modified release of at least one active principle and oral galenic form comprising same
INVENTOR(S): Dargelas, Frederic; Guimberteau, Florence; Castan, Catherine; Meyrueix, Remi; Soula, Gerard
PATENT ASSIGNEE(S): Flamel Technologies, Fr.
SOURCE: PCT Int. Appl., 50pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007036671	A2	20070405	WO 2006-FR50944	20060927
WO 2007036671	A3	20070524		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
FR 2891459	A1	20070406	FR 2005-52985	20050930
FR 2891459	B1	20071228		
CA 2624372	A1	20070405	CA 2006-2624372	20060927
EP 1931320	A2	20080618	EP 2006-831231	20060927
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009510036	T	20090312	JP 2008-532838	20060927
CN 101277684	A	20081001	CN 2006-80036080	20080328
US 20090220611	A1	20090903	US 2009-992769	20090320
PRIORITY APPLN. INFO.:			FR 2005-52985 A	20050930
			WO 2006-FR50944 W	20060927

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention concerns microparticle systems with modified release of oral active principle(s). The invention aims at providing a novel multimicroparticle galenic system operating in accordance with a dual time-dependent and pH-dependent release mechanism, which enables the following three parameters to be adjusted independently of one another: (a) the latent period preceding the release of the active principle in the stomach; (b) the pH triggering the release of the active principle in the intestine; (c) the release speed of the active principle. This is achieved through the use of coated microparticles made from particles of active principle each coated with two coating films A and B. Film A comprises: film-forming (co)polymer (A1) insol. in fluids of the gastrointestinal tract, Et cellulose (co)polymer (A2) soluble in fluids of the gastrointestinal tract, plasticizing polyvinylpyrrolidone (A3), and castor oil and optionally a surfactant and/or magnesium stearate lubricant

(A4). Film B comprises a hydrophilic polymer (B1) bearing ionized groups with neutral pH (Eudragit L100-55) and a hydrophobic compound (B2) (Lubritab). Metformin hydrochloride and povidone were dissolved in water and spray-dried over neural microspheres. The microspheres were then coated to obtain prolonged-release metformin microparticles.

IT 132539-06-1, Olanzapine=
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microparticles with modified release of at least one active principle and oral galenic form comprising same)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L33 ANSWER 45 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:265980 HCAPLUS
DOCUMENT NUMBER: 146:448301
TITLE: Synergistic pharmaceutical compositions containing olanzapine and analgetic drugs
INVENTOR(S): Shannon, Harlan E.; Womer, Daniel E.
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Hung. Pat. Appl., 38 pp.
CODEN: HUXXCV
DOCUMENT TYPE: Patent
LANGUAGE: Hungarian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
HU 9903375	A2	20000228	HU 1999-3375	19970324
HU 9903375	A3	20000428		
PRIORITY APPLN. INFO.:			HU 1999-3375	19970324

AB The subject of the invention is a pharmaceutical product, which contains olanzapine or its medically acceptable salt and one or more pain relieving active ingredients. The product according to the invention has a synergetic effect. Thus tablets were prepared from a composition (weight parts):
hydroxypropyl cellulose 4.0; olanzapine 1.18; ibuprofen 3.0; lactose 79.32; Crospovidon 5; cellulose 10; magnesium stearate 0.5. The tablets were coated with a mixture of hydroxypropyl methylcellulose, polyethylene glycol, polysorbat 80 and titania.

IT 132539-06-1, Olanzapine
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synergistic pharmaceutical compns. containing olanzapine and analgetic drugs)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 132539-06-1D, Olanzapine, salts, solvates
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synergistic pharmaceutical compns. containing olanzapine and analgetic drugs)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



L33 ANSWER 46 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:233432 HCAPLUS
DOCUMENT NUMBER: 146:408229
TITLE: Rapidly dispersing solid oral composition comprising ondansetron
INVENTOR(S): Krishna, Divi Murali; Deshmukh, Abhijit Mukund; Dhanorkar, Vipin Tatyasaheb; Mohan, Mailatur Sivaraman
PATENT ASSIGNEE(S): Dr. Reddy's Laboratories Ltd., India
SOURCE: Indian Pat. Appl., 18pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2002MA00301	A	20050304	IN 2002-MA301	20020418
PRIORITY APPLN. INFO.:			IN 2002-MA301	20020418

AB The present invention relates to the rapidly dispensing solid oral compns. comprising olanzapine or ondansetron. The present invention further discloses the wet granulation or direct compression method of producing such rapidly dispersing compns. The pharmaceutically accepted solvate, salts, enantiomers or mixts. thereof including racemic mixture of olanzapine and onadansetron are contemplated to be within the scope of the present invention. Thus, tablet was prepared comprising ondansetron 4 mg, crosspovidone 33.86 mg, aspartame 1.5 mg, Avicel CE15 4 mg, sodiumlauryl sulfate 0.135 mg, strawberry flavor 0.5 mg.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rapidly dispersing solid oral composition comprising ondansetron)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L33 ANSWER 47 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:181484 HCAPLUS
DOCUMENT NUMBER: 146:365595
TITLE: Oral olanzapine tablet formulations with coating containing polyethylene glycol
INVENTOR(S): Reddy, Pallempalli Venkata Siva; Reddy, Billa Praveen; Mohan, Mailatur Sivaraman
PATENT ASSIGNEE(S): Dr. Reddy's Laboratories Ltd., India
SOURCE: Indian Pat. Appl., 14pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2002MA00235	A	20050304	IN 2002-MA235	20020401
PRIORITY APPLN. INFO.:			IN 2002-MA235	20020401

AB The present invention is directed towards the oral tablet dosage form of olanzapine consisting essentially of the polyethylene glycol coating applied directly on the core tablet containing olanzapine Form I polymorph as active ingredient. The coated tables of olanzapine prepared in accordance with the present invention have acceptable stability as per ICH guidelines and are bioequivalent to the com. available Zyprexa tablets.

IT 132539-06-1, Olanzapine
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral olanzapine tablet formulations with coating containing polyethylene glycol)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L33 ANSWER 48 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:87383 HCAPLUS
DOCUMENT NUMBER: 146:169366
TITLE: Oral, quickly disintegrating film, which cannot be spit out, for a neuroleptic drug
INVENTOR(S): Obermeier, Petra; Kohr, Thomas; Kramer, Kai-Thomas; Klokkers, Karin
PATENT ASSIGNEE(S): Hexal A.-G., Germany
SOURCE: PCT Int. Appl., 25pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007009801	A2	20070125	WO 2006-EP7177	20060720
WO 2007009801	A3	20070621		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
DE 102005033943	A1	20070222	DE 2005-102005033943	20050720
AU 2006271865	A1	20070125	AU 2006-271865	20060720
CA 2615533	A1	20070125	CA 2006-2615533	20060720
EP 1904029	A2	20080402	EP 2006-776333	20060720
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009501752	T	20090122	JP 2008-521902	20060720
ZA 2008000976	A	20090826	ZA 2008-976	20060720
MX 2008000847	A	20080326	MX 2008-847	20080118
IN 2008CN00285	A	20080919	IN 2008-CN285	20080118
CN 101287445	A	20081015	CN 2006-80034510	20080319
US 20080200452	A1	20080821	US 2008-996382	20080328
PRIORITY APPLN. INFO.:			DE 2005-102005033943A	20050720
			WO 2006-EP7177 W	20060720

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to a film-shaped, single-layered and cavity-free preparation that does not contain any surfactants nor effervescent additives and flavor masking agents, comprised of film forming agents, one or more gelling agents and of one or more active substances selected from the group of neuroleptic drugs. Thus a film included (weight/weight%): olanzapine 50; hydroxypropylmethylcellulose 30; ethylcellulose 5; paraffin oil 5; D-sorbitol 5; 1,3-butane diol 2.5; iso-Pr palmitate 2.5.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral, quickly disintegrating film, which cannot be spit out, for a neuroleptic drug)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



L33 ANSWER 49 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:1229195 HCAPLUS
DOCUMENT NUMBER: 146:777
TITLE: Method for the treatment of drug-induced sexual dysfunction
INVENTOR(S): Pyke, Robert
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b. H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 37pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006125042	A1	20061123	WO 2006-US19155	20060517
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2608363	A1	20061123	CA 2006-2608363	20060517
US 20060264511	A1	20061123	US 2006-383793	20060517
EP 1888071	A1	20080220	EP 2006-770528	20060517
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008540673	T	20081120	JP 2008-512487	20060517
PRIORITY APPLN. INFO.:			US 2005-682760P P	20050519
			WO 2006-US19155 W	20060517

AB The invention relates to a method for the treatment of drug-induced sexual dysfunctions comprising the administration of a therapeutically effective amount of flibanserin.

IT 132539-06-1, Olanzapine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treatment of drug-induced sexual dysfunction)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	9	THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 50 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:1181075 HCAPLUS
DOCUMENT NUMBER: 145:500123
TITLE: Application of β-funaltrexamine (β-FNA) in preparing the medicine for treating schizophrenia
INVENTOR(S): Jin, Meilei; Hao, Junguo; Zou, Hong; Xie, Qinglian; Zhao, Guoping
PATENT ASSIGNEE(S): Shanghai Casb Biotechnology Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 17pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1853633	A	20061101	CN 2005-10025537	20050429

PRIORITY APPLN. INFO.: CN 2005-10025537 20050429

AB The patent relates to application of (E)-4-[[(5α,6β)-17-cyclopropyl methyl-4,5-epoxy-3,14-dihydroxy morphinan-6-yl]amino]-4-oxo-2-butanoic acid Me ester or its pharmaceutically acceptable salts to prepare the medicine for treating schizophrenia. The medicine also contains clozapine, olanzapine, risperidone or the combination thereof, and pharmaceutically acceptable carrier. β-FNA can effectively treat and improve schizophrenia and individual cognitive ability.

IT 132539-06-1, Olanzapine
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(application of β-funaltrexamine (β-FNA) in preparing medicine for treating schizophrenia)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L33 ANSWER 51 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:952769 HCAPLUS
DOCUMENT NUMBER: 145:342445
TITLE: Dual controlled release osmotic device comprising two different active agents
INVENTOR(S): Vergez, Juan A.; Ricci, Marcelo A.
PATENT ASSIGNEE(S): Osmotica Corp., Virgin I. (Brit.)
SOURCE: U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. Ser. No. 321,736.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060204578	A1	20060914	US 2006-355315	20060215
US 20030185882	A1	20031002	US 2001-992488	20011106
US 20060177510	A1	20060810	US 2005-321736	20051229
PRIORITY APPLN. INFO.:			US 2001-992488	B3 20011106
			US 2005-321736	A2 20051229

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodiments include a dosage form that provides therapeutically effective levels of a first active agent and a second active agent in a mammal for an extended period of time following oral administration. An osmotic device containing a bilayered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. The layers of the core are in stacked, substantially concentric or substantially eccentric arrangement. For example, bilayered controlled release tablet was prepared containing first layer comprised of oxybutynin hydrochloride 5.15 mg, Myvacet 5-07 10.80 mg, Povidone K25 5.40 mg, microcryst. cellulose spheres 68.68 mg, cellulose acetophtalate 4.10 mg, colloidal silicon dioxide 0.60 mg, and magnesium stearate 10.80 mg; second layer comprised of tolterodine L-tartrate 2.92 mg, Myvaplex 600P NF 82.07 mg, red iron oxide 0.15 mg, microcryst. cellulose spheres 67.76 mg, cellulose acetophtalate 4.10 mg, colloidal silicon dioxide 1.80 mg, croscarmellose sodium 1.80 mg, and magnesium stearate 0.75 mg.
IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dual controlled-release osmotic device comprising two different active agents)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L33 ANSWER 52 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:921758 HCAPLUS
DOCUMENT NUMBER: 145:299659
TITLE: Rapidly disintegrating dosage forms comprising magnesium carbonate heavy
INVENTOR(S): Kristjansson, Torfi E.
PATENT ASSIGNEE(S): Actavis Group Hf., Iceland
SOURCE: PCT Int. Appl., 23pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2006092812	A2	20060908	WO 2006-IS5		20060302
WO 2006092812	A3	20061221			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
CA 2599308	A1	20060908	CA 2006-2599308		20060302
EP 1863443	A2	20071212	EP 2006-711375		20060302
EP 1863443	B1	20091021			
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU					
DE 202006020222	U1	20080710	DE 2006-202006020222		20060302
JP 2008531681	T	20080814	JP 2007-557680		20060302
AT 446084	T	20091115	AT 2006-711375		20060302
CN 101132764	A	20080227	CN 2006-80006978		20070903
US 20080166406	A1	20080710	US 2007-885417		20071017
PRIORITY APPLN. INFO.:			IS 2005-7724	A	20050302
			WO 2006-IS5	W	20060302

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A rapidly disintegrating dosage form containing magnesium carbonate heavy is described, which disintegrates upon contact with moisture. The dosage forms can be either dispersible or orodispersible tablets and can accommodate widely different active principles. The magnesium carbonate heavy is an excellent dispersant under basic and neutral conditions, and gives the tablets a smooth mouth-feel. Thus, tablets contained lamotrigine 5, magnesium carbonate heavy 122, Avicel PH102 29, Povidone 4, HPC 8, sodium saccharin 2, Crospovidone 8, microcryst. cellulose + guar gum 10, black currant flavor Silarom 2, and Mg stearate 2 mg/tablet.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rapidly disintegrating dosage forms comprising magnesium carbonate

heavy)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 53 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:845515 HCAPLUS
DOCUMENT NUMBER: 145:256184
TITLE: Rapidly disintegrating composition of an antipsychotic drug
INVENTOR(S): Nagareddy, Chandra Sekhara Reddy; Cheruvu, Ramesh; Deo, Kishor, Dattatray; Meenakshisunderam, Sivakumaran
PATENT ASSIGNEE(S): Aurobindo Pharma Limited, India
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006087629	A2	20060824	WO 2006-IB330	20060220
WO 2006087629	A3	20061102		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
IN 2005CH00143	A	20070316	IN 2005-CH143	20050221
PRIORITY APPLN. INFO.:			IN 2005-CH143 A	20050221

AB The present invention relates to rapidly disintegrating dosage form of olanzapine with no binding agent comprising of about 1-10% olanzapine, about 1-10% of disintegrant, about 70-85% of filler, and about 0.4-7% of lubricant.
IT 132539-06-1, Olanzapine
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(rapidly disintegrating composition of antipsychotic olanzapine)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 54 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:796343 HCAPLUS
DOCUMENT NUMBER: 145:195791
TITLE: A pharmaceutical composition containing olanzapine as the active agent and a process for the preparation thereof
INVENTOR(S): Vladovicova, Beata; Lehocky, Mikulas; Kormanova, Viera; Hubinova, Viera
PATENT ASSIGNEE(S): Zentiva, A.S., Czech Rep.
SOURCE: PCT Int. Appl., 15pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006081779	A2	20060810	WO 2006-CZ2	20060119
WO 2006081779	A3	20070503		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
CZ 297214	B6	20061011	CZ 2005-63	20050202
PRIORITY APPLN. INFO.:			CZ 2005-63 A	20050202

AB A pharmaceutical composition is disclosed containing, as the active agent, olanzapine and further a filler and auxiliary substances, in the form of tablet obtainable by direct tabletting, the core of the tablet containing olanzapine in an amount of 0.5 to 20 w.% and a pharmaceutically acceptable filler in an amount of 35 to 99 w.%, preferably up to 95 w.%, with the particle sizes ranging from 10 to 1000 μm, preferably from 50 to 400 μm, the core being optionally coated, in which case the coating contains 1 to 10 w.% of polyethyleneglycol after drying. The pharmaceutically acceptable filler is selected from the series of microcryst. cellulose, lactose, the polyalcs. mannitol or sorbitol, calcium hydrogenphosphate, and a combination of microcryst. cellulose with a mono- or oligosaccharide or polyalc. A process for the preparation of tablets is also disclosed.

IT 132539-06-1, Olanzapine
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmaceutical composition containing olanzapine as the active agent)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 55 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:700113 HCAPLUS
DOCUMENT NUMBER: 145:130884
TITLE: Orally disintegrating composition of olanzapine or donepezil
INVENTOR(S): Kroselj, Vesna; Kolaric, Sasa; Jakse, Renata
PATENT ASSIGNEE(S): Krka Tovarna Zdravil, D.D., Novo Mesto, Slovenia
SOURCE: Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1681048	A1	20060719	EP 2005-664	20050114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
AU 2006205817	A1	20060720	AU 2006-205817	20060113
WO 2006074951	A2	20060720	WO 2006-EP284	20060113
WO 2006074951	A3	20070426		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1845954	A2	20071024	EP 2006-701464	20060113
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
NO 2007004087	A	20071009	NO 2007-4087	20070807
ZA 2007006692	A	20080730	ZA 2007-6692	20070813
PRIORITY APPLN. INFO.:			EP 2005-664 A	20050114
			WO 2006-EP284 W	20060113

AB The invention relates to orally disintegrating compns. of olanzapine or donepezil which show a very quick release of the active ingredient, as well as a process for their preparation Tablets were prepared containing olanzapine, mannitol, microcryst. cellulose, low-substituted hydroxypropyl cellulose, Aspartame, Crospovidone , Ca silicate, Mg stearate.
IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(orally disintegrating composition of olanzapine or donepezil)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 56 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:699918 HCAPLUS
DOCUMENT NUMBER: 145:152709
TITLE: Stable, non-crystalline formulation comprising olanzapine
INVENTOR(S): Duddu, Sarma; Zhang, Jiang; Lechuga, David; Miller, Danforth
PATENT ASSIGNEE(S): Nektar Therapeutics, USA
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006076124	A2	20060720	WO 2005-US45696	20051215
WO 2006076124	A3	20060921		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-636667P P 20041216

AB One or more embodiments of the invention provide various novel formulations comprising olanzapine that are non-crystalline, which exhibit desired or improved stability, and/or possesses desired micromeritic properties and/or are otherwise improvements over known olanzapine formulations. The olanzapine-containing formulations may be administered to a user to treat psychotic conditions, especially schizophrenia and schizophrenic conditions, and/or mania. Thus, com. available crystalline olanzapine was dissolved in water at 1-25% solids content, hydroxypropyl cellulose was added to the solution in a weight ratio of about 0.1:10 to 10:0.1, and the solution was spray dried. The processing resulted in the formation of a noncryst. form of olanzapine comprising a free-flowing powder with a Tg above about 40°, or a dry Tg of the particles of above about 90°, or both.

IT 132539-06-1, Olanzapine
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of stable, non-crystalline formulation comprising olanzapine)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 57 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:681023 HCAPLUS
DOCUMENT NUMBER: 145:174286
TITLE: Pharmaceutical compositions comprising o-acetylsalicyl derivatives of amino saccharides and amino acids
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006074114	A2	20060713	WO 2005-US47669	20060103
WO 2006074114	A3	20070503		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20060166901	A1	20060727	US 2005-320530	20051229
AU 2006204136	A1	20060713	AU 2006-204136	20060103
CA 2593055	A1	20060713	CA 2006-2593055	20060103
EP 1843661	A2	20071017	EP 2005-856124	20060103
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008526774	T	20080724	JP 2007-549694	20060103
CN 101128117	A	20080220	CN 2005-80048674	20070824

PRIORITY APPLN. INFO.:			
US 2005-640225P	P	20050103	
US 2005-320530	A	20051229	
WO 2005-US47669	W	20060103	

OTHER SOURCE(S): MARPAT 145:174286

AB The embodiments described herein include a composition and method of treatment using compns. that include at least 1 acetylsalicyl derivative The compns. and methods are useful in preventing and treating disorders and syndromes associated with anyone of the nervous, vascular, musculoskeletal, or cutaneous systems. N-(O-acetylsalicyl)-D-galactosamine 5 g was dissolved in warm propylene glycol 35 mL, and the solution thus obtained was mixed with hydrophilic ointment or oil-in-water cream (60 g). The cream thus prepared had pH 3.9 and contained 5% N-(O-acetylsalicyl)-D-galactosamine.

IT 132539-06-1, Olanzapine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. comprising acetylsalicyl derivs. of amino saccharides and amino acids)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L33 ANSWER 58 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:631165 HCAPLUS
DOCUMENT NUMBER: 145:110313
TITLE: Pharmaceutical compositions comprising an agent with serotonin receptor modulating activity for sleep disorders
INVENTOR(S): Rariy, Roman V.; Heffernan, Michael
PATENT ASSIGNEE(S): Collegium Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006069030	A1	20060629	WO 2005-US46049	20051220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005319367	A1	20060629	AU 2005-319367	20051220
CA 2590802	A1	20060629	CA 2005-2590802	20051220
EP 1833467	A1	20070919	EP 2005-854713	20051220
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008524332	T	20080710	JP 2007-548372	20051220
US 20080200508	A1	20080821	US 2007-793392	20070619
CN 101132777	A	20080227	CN 2005-80043729	20070620
IN 2007DN04915	A	20070817	IN 2007-DN4915	20070626
KR 2007087678	A	20070828	KR 2007-716730	20070720
PRIORITY APPLN. INFO.:			US 2004-637655P P	20041220
			WO 2005-US46049 W	20051220

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB Pharmaceutical compns. are provided for the pharmacol. treatment of breathing disorders and, more specifically, to compns. containing agents having serotonin receptor modulating activity for the alleviation of sleep apnea (central and obstructive) and other sleep-related breathing disorders wherein the active ingredients are released such as to extend effective blood plasma concns. across the period of sleep. For example, ondansetron immediate release tablets were prepared containing ondansetron HCl dihydrate 9.98 mg, lactose 29.14 mg, Prosolv 50 29.14 mg, Ac-Di-Sol 3.75 mg, SDS 1.5 mg, Aerosil 0.75 mg, and Mg stearate 0.75 mg. Ondansetron immediate release tablets were then coated with Eudragit L100/S100 blend to obtain delayed release tablets.
IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral compns. comprising serotonin receptor modulator for treatment of

sleep disorders)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 59 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:577864 HCAPLUS
DOCUMENT NUMBER: 145:34293
TITLE: Solvent-free taste masked pharmaceutical compositions
INVENTOR(S): Kumaraperumal, Natrajan; Palaniswamy, Suresh; Davila, Pablo
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060127479	A1	20060615	US 2004-961728	20041008
PRIORITY APPLN. INFO.:			US 2004-961728	20041008

AB Disclosed is a taste masked pharmaceutical composition comprising: (a) a core containing a bitter-tasting drug, such as cetirizine dihydrochloride; and (b) a coating comprising a pharmaceutically acceptable cationic polymer based on mono- or dialkylaminoalkyl methacrylate and neutral acrylic or methacrylic esters, wherein the alkyl group independently has 1 to 6 carbon atoms, wherein the coating is applied to the surface of the core. The taste masked pharmaceutical compns. of the invention may be prepared without using an organic solvent or a cyclodextrin.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coating for taste masking in oral pharmaceuticals)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L33 ANSWER 60 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:100738 HCAPLUS
DOCUMENT NUMBER: 144:198849
TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients
INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060024365	A1	20060202	US 2005-134633	20050519
IN 2002MU00697	A	20040529	IN 2002-MU697	20020805
IN 193042	A1	20040626		
IN 2002MU00699	A	20040529	IN 2002-MU699	20020805
IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
US 20040096499	A1	20040520	US 2003-630446	20030729

PRIORITY APPLN. INFO.:

IN 2002-MU697	A	20020805
IN 2002-MU699	A	20020805
IN 2003-MU80	A	20030122
IN 2003-MU82	A	20030122
US 2003-630446	A2	20030729

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.
IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L33 ANSWER 61 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:56947 HCAPLUS
DOCUMENT NUMBER: 144:135292
TITLE: Oral disintegrating tablets with fillers for odor-masking
INVENTOR(S): Ge, Jilong; Fang, Yandong; Liu, Jianan; Tu, Yongrui
PATENT ASSIGNEE(S): Changzhou No.4 Pharmaceutical Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 12 pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1613442	A	20050511	CN 2003-10108459	20031106
CN 1274298	C	20060913		

PRIORITY APPLN. INFO.: CN 2003-10108459 20031106

AB The oral disintegrating tablet is comprised of medical granule 5%-60% and pharmaceutical adjuvant. The oral disintegrating tablet is prepared by the following steps of preparing covering odor medical granule and preparing oral disintegrating tablet. The covering odor medical granule is prepared by grinding by gas into <5-50 μm, mixing medicine material with filling material and disintegrating agent, preparing wet granule with water containing adhesive, oven drying, wetting with 90%-100% ethanol (the dosage is 40%-120% of medical granule), screening, choosing granule of NO. 3-NO. 6 screen, oven drying, adding plasticizer and lubricant, coating with fluidized-bed to weight 6-20%, screening to obtain medical granule. The oral disintegrating tablet is prepared by adding filling material, disintegrating agent, sweetening agent, flavoring agent, lubricant and glidant, mixing, and tabletting, according to the ratio of 5%-60%. The covering odor medicine is risperidone, olanzapine, clozapine, estazolam, zopiclone, and Laolaxiyang (sic), and the content in the granule is 5%-60%. The pharmaceutic adjuvant is routine filling material, disintegrating agent, sweetening agent, flavouring agent, lubricant and glidant. The filling material is starch, dextrin, calcium sulfate, and calcium phosphate, and the content in the granule is 10%-90%. The disintegrating agent is microcryst. cellulose, low substitutional hydroxypropyl, crosslinked polyethylene pyrrolidone, and carboxymethyl sodium starch, and the content in the granule is 5%-40% The adhesive is 5%-20% starch or 1%-15% low viscosity Me sodium fiber, and the content in the granule is 5%-15% The coating material is from one or the mixture of Eudragit E 100, hydroxypropyl methylcellulose, and hydroxy Et cellulose. The plasticizer is tri-Et citrate, castor oil, di-Et phthalate, and the lubricant is talc powder. For example, disintegrating tablets contained risperidone 20, corn starch 80 and microcryst. cellulose 20 g with coatings of ethanol, Eudragit E100, tri-Et citrate and talc.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral disintegrating tablets with fillers and sweeteners and coatings for odor-masking)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 62 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1354712 HCAPLUS
DOCUMENT NUMBER: 144:94350
TITLE: A method of improving the medical treatment of pain
INVENTOR(S): Christgau, Stephan; Hansen, Christian; Nilsson, Henrik
PATENT ASSIGNEE(S): Osteologix A/S, Den.
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123192	A2	20051229	WO 2005-DK401	20050617
WO 2005123192	A3	20061228		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005254154	A1	20051229	AU 2005-254154	20050617
CA 2570503	A1	20051229	CA 2005-2570503	20050617
EP 1758652	A2	20070307	EP 2005-748539	20050617
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
JP 2008502608	T	20080131	JP 2007-515782	20050617
US 20060122274	A1	20060608	US 2005-269289	20051107
US 7595342	B2	20090929		
WO 2006089546	A1	20060831	WO 2005-DK710	20051107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1855654	A1	20071121	EP 2005-799508	20051107
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20080317849	A1	20081225	US 2008-629612	20080304
US 20080221213	A1	20080911	US 2008-817181	20080430

PRIORITY APPLN. INFO.: DK 2004-947 A 20040617

DK 2003-691	A	20030507
DK 2003-932	A	20030620
DK 2003-1820	A	20031209
US 2003-528442P	P	20031209
WO 2004-DK328	A2	20040506
WO 2005-DK140	A2	20050228
WO 2005-DK401	W	20050617
WO 2005-DK404	A2	20050617
WO 2005-DK710	W	20051107

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods for improving pain management in a mammal, the methods comprising administering a combination of a strontium-containing compound and a second therapeutically and/or prophylactically active substance selected from the group consisting of analgesic agents, anti-inflammatory agents and palliative agents to the mammal. Pharmaceutical compns. for use in such methods, comprising a strontium-containing compound and a second therapeutically and/or prophylactically active substance selected from the group consisting of analgesic agents, anti-inflammatory agents and palliative agents. For example, a tablet containing naproxen 250, strontium malonate 210, lactose 100, corn starch 30, and magnesium stearate 10 mg was formulated.

IT 132539-06-1, Zyprexa
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of improving medical treatment of pain by administering combination of strontium-containing compound and second active substance)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 63 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:735332 HCAPLUS
DOCUMENT NUMBER: 143:199900
TITLE: Composition comprising salts or hydrates or polymorphs of idazoxan or its derivatives
INVENTOR(S): Bougaret, Joel; Avan, Jean-Louis; Segonds, Roland
PATENT ASSIGNEE(S): Pierre Fabre Medicament, Fr.
SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Ser. No. 722,451.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050176798	A1	20050811	US 2004-974675	20041028
US 7595335	B2	20090929		
FR 2861299	A1	20050429	FR 2003-12626	20031028
FR 2861299	B1	20060127		
US 20050090537	A1	20050428	US 2003-722451	20031128
US 7338970	B2	20080304		
AU 2004285316	A1	20050512	AU 2004-285316	20041028
CA 2542752	A1	20050512	CA 2004-2542752	20041028
EP 1682124	A1	20060726	EP 2004-805330	20041028
EP 1682124	B1	20071219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1870993	A	20061129	CN 2004-80031500	20041028
BR 2004016006	A	20070102	BR 2004-16006	20041028
JP 2007509911	T	20070419	JP 2006-537357	20041028
MX 2006004717	A	20060705	MX 2006-4717	20060427
HK 1094769	A1	20080328	HK 2007-100684	20070119
US 20080262067	A1	20081023	US 2008-103344	20080415

PRIORITY APPLN. INFO.:		
FR 2003-12626	A	20031028
US 2003-722451	A2	20031128
US 2004-974675	A2	20041028
WO 2004-FR2773	W	20041028

AB The present invention discloses a pharmaceutical composition comprising idazoxan or derivs. and their therapeutically acceptable salts, racemates, optically active isomers and polymorphs. Thus, a tablet was prepared comprising idazoxan hydrochloride 20%, microcryst. cellulose 10%, glyceryl behenate 5%, colloidal silica 0.1% and lactose monohydrate to 100%. The addition of idazoxan to the treatment with fluphenazine in patients with schizophrenia to control extrapyramidal symptoms led to significant reduction in the symptoms in comparison with fluphenazine monotherapy.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combination with; composition comprising salts or hydrates or polymorphs of idazoxan or its derivs.)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 64 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:698356 HCAPLUS
DOCUMENT NUMBER: 143:179645
TITLE: Compositions containing atypical antipsychotics and azabicyclic compounds for treating CNS disorders
INVENTOR(S): Brodney, Michael A.; Howard, Harry R.
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050171086	A1	20050804	US 2005-48013	20050128
CA 2555172	A1	20050909	CA 2005-2555172	20050117
WO 2005082370	A1	20050909	WO 2005-IB106	20050117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1715868	A1	20061102	EP 2005-702269	20050117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
BR 2005007250	A	20070626	BR 2005-7250	20050117
JP 2007519705	T	20070719	JP 2006-550332	20050117
MX 2006008647	A	20060904	MX 2006-8647	20060728
PRIORITY APPLN. INFO.:			US 2004-539939P P	20040129
			WO 2005-IB106 W	20050117

OTHER SOURCE(S): MARPAT 143:179645
AB Disclosed is an aminomethylpyridyloxymethyl/benzisoxazole substituted azabicyclic compound, a pharmaceutical composition comprising same, and a method of treating one or more CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression. For example, capsules for Parkinson's disease contained ziprasidone hydrochloride 200, benzisoxazole substituted azabicyclic compd 20, Methocel E3 222, lactose monohydrate 222, Aerosil 10, SLS 10 mg.
IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination chemotherapy containing atypical antipsychotics and azabicyclic compds for treating CNS disorders)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L33 ANSWER 65 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:638703 HCAPLUS
DOCUMENT NUMBER: 143:139194
TITLE: Buccal dosage forms for extended drug release
INVENTOR(S): Jain, Rajesh; Jindal, Kour Chand; Singh, Sukhjeet
PATENT ASSIGNEE(S): Panacea Biotec Ltd., India
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065640	A1	20050721	WO 2005-IN3	20050105
WO 2005065640	A8	20051208		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2004DE00024	A	20060210	IN 2004-DE24	20040106
PRIORITY APPLN. INFO.:			IN 2004-DE24 A	20040106
			IN 2004-DE26 A	20040106

AB Buccal dosage form compns., preferably of poorly bioavailable drug(s), or drug(s) which undergo extensive presystematic metabolism, are provided. The compns. provide extended release of the drug in the oral cavity, and are preferably in the taste masked form. A process of preparing of such compns. is also provided. Thus, a tablet contained sumatriptan succinate 25.0, Indion-204 75.0, maltodextrin 48.0, sucrose 30.0, CM-cellulose 18.0, HPMC 8.0, HPC 8.0, citric acid 15.0, NaCl 5.0, and Povidone 3.0 25 mg/tablet.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(buccal dosage forms for extended drug release)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 66 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:369131 HCAPLUS
DOCUMENT NUMBER: 142:417199
TITLE: Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs
INVENTOR(S): Bougaret, Joel; Avan, Jean-Louis; Segonds, Roland
PATENT ASSIGNEE(S): Fr.
SOURCE: U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050090537	A1	20050428	US 2003-722451	20031128
US 7338970	B2	20080304		
FR 2861299	A1	20050429	FR 2003-12626	20031028
FR 2861299	B1	20060127		
AU 2004285316	A1	20050512	AU 2004-285316	20041028
CA 2542752	A1	20050512	CA 2004-2542752	20041028
WO 2005041956	A1	20050512	WO 2004-FR2773	20041028
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050176798	A1	20050811	US 2004-974675	20041028
US 7595335	B2	20090929		
EP 1682124	A1	20060726	EP 2004-805330	20041028
EP 1682124	B1	20071219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1870993	A	20061129	CN 2004-80031500	20041028
BR 2004016006	A	20070102	BR 2004-16006	20041028
JP 2007509911	T	20070419	JP 2006-537357	20041028
AT 381331	T	20080115	AT 2004-805330	20041028
PT 1682124	E	20080305	PT 2004-805330	20041028
ES 2297525	T3	20080501	ES 2004-805330	20041028
MX 2006004717	A	20060705	MX 2006-4717	20060427
HK 1094769	A1	20080328	HK 2007-100684	20070119
US 20080113022	A1	20080515	US 2008-15788	20080117

PRIORITY APPLN. INFO.:
FR 2003-12626 A 20031028
US 2003-722451 A2 20031128
WO 2004-FR2773 W 20041028

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A pharmaceutical composition comprises an idazoxan salt or idazoxan hydrate 5, microcryst. cellulose 10, lubricant 5, colloidal silica 0.1, and lactose monohydrate qs to 100%. Crystallog. anal. by powder x-ray diffraction was carried out on idazoxan polymorphs.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition based on idazoxan or salts or hydrates or polymorphs)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 67 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:158522 HCAPLUS
DOCUMENT NUMBER: 142:246155
TITLE: Novel nanoparticulate metaxalone compositions comprising surface stabilizers and use for treating musculoskeletal disorders
INVENTOR(S): Pruitt, John D.; Ryde, Tuula A.; Bosch, William H.
PATENT ASSIGNEE(S): Elan Pharma International, Ltd., Ire.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005016310	A1	20050224	WO 2004-US19108		20040726
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2534924	A1	20050224	CA 2004-2534924		20040726
EP 1651189	A1	20060503	EP 2004-776615		20040726
EP 1651189	B1	20081203			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
JP 2007501839	T	20070201	JP 2006-523181		20040726
AT 415946	T	20081215	AT 2004-776615		20040726
ES 2318330	T3	20090501	ES 2004-776615		20040726
US 20050063913	A1	20050324	US 2004-912552		20040806
PRIORITY APPLN. INFO.:			US 2003-493446P	P	20030808
			WO 2004-US19108	W	20040726

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to novel compns. of metaxalone, comprising metaxalone particles having an effective average particle size of less than about 2000 nm and at least one surface stabilizer that is preferably adsorbed to or associated with the surface of the drug particles. The invention further discloses a method of making a nanoparticulate metaxalone composition comprising contacting metaxalone and at least one surface stabilizer for a time and under conditions sufficient to provide a nanoparticulate metaxalone composition The one or more surface stabilizers can be contacted with metaxalone either before, preferably during, or after size reduction of the metaxalone. The present invention is also directed to methods of treatment using the nanoparticulate metaxalone compns. of the invention for treatment of musculoskeletal disorders.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel nanoparticulate metaxalone compns. comprising surface stabilizers and use for treating musculoskeletal disorders)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 68 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:99341 HCAPLUS
DOCUMENT NUMBER: 142:162690
TITLE: Oral pharmaceutical formulations of olanzapine
INVENTOR(S): Dubey, Vivek Mahendrakumar; Deshmukh, Abhijit Mukund; Sethi, Sanjeev Kumar; Malik, Rajiv
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009407	A2	20050203	WO 2004-IB51335	20040729
WO 2005009407	A3	20060302		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2006DN00559	A	20070817	IN 2006-DN559	20060202
PRIORITY APPLN. INFO.:			IN 2003-DE939 A	20030729
			WO 2004-IB51335 W	20040729

AB The present invention relates to olanzapine formulations stable to discoloration. The formulations include olanzapine particles or powders, and a coating on the olanzapine particles or the powder. The coating comprises lactose and/or mannitol and optionally 1 or more excipients. Thus, tablets contained olanzapine 20, lactose/mannitol 270, Avicel PH-101 48, HPMC/HPC/Plasdone S-630 15, Crospovidone 6, Avicel PH-112 20, Mg stearate 2, and talc 3 mg/tablet, and water/isopropanol qs.
IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral pharmaceutical formulations of olanzapine)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 69 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:71078 HCAPLUS
DOCUMENT NUMBER: 142:183422
TITLE: Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
INVENTOR(S): Thanoo, B. C.; Murtagh, Jim; Johns, Gonto
PATENT ASSIGNEE(S): Oakwood Laboratories, L.L.C., USA
SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007122	A2	20050127	WO 2004-US23324	20040719
WO 2005007122	A3	20050909		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2533314	A1	20050127	CA 2004-2533314	20040719
US 20050042294	A1	20050224	US 2004-894956	20040719
EP 1660039	A2	20060531	EP 2004-778698	20040719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2008518881	T	20080605	JP 2006-520417	20040719
PRIORITY APPLN. INFO.:			US 2003-488573P P	20030718
			WO 2004-US23324 W	20040719

AB Polymer and drug containing compns. and method of preparing such compns. are disclosed. The dispersed phase formulation has a polymer, a pharmaceutically or biol. active agent and a small fraction of low pKa acid additive. Stable, filter sterilizable, non-gelling solns. containing e.g. GnRH analogs at least at levels typically used in sustained release formulations and a method of increasing solubility of a high level of a GnRH analog or a freeze-dried antagonist of GnRH in a polymer containing solution are also disclosed. The amount of the acid additive in the polymer solution is such that it is sufficient to increase the solubility of the high level of the GnRH analog in the polymer solution without affecting the release characteristics of the microspheres prepared therefrom. For example, control of mol. weight (MW) reduction of PLGA in dispersed phase with or without leuprolide was studied. There was reduction in MW upon incubating the dispersed phase consisting of RG503H, dichloromethane (DCM), and MeOH. The presence of lactic acid, glycolic acid, and oligomer acids reduced the reduction in MW. Under the exptl. conditions, acids with very low pKa, such as lactic (pKa 3.08) and glycolic (pKa 3.83) acids were more effective in

preventing MW reduction caused by methanol. Even with a fraction of the acid (less than or equal to 1 mol% to that of the nucleophilic compound, methanol) in the dispersed phase, there was influence on the mol. weight reduction There was a considerable reduction in the mol. weight of the polymer in the dispersed phase containing leuprolide. Again, presence of lactic acid, glycolic acid, and oligomer acids reduced the extent of mol. weight reduction, much more efficiently compared to acetic acid.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sustained-release compns. comprising polymer matrix and acid additive for preventing polymer mol. weight reduction, impurity formation and gelling in presence of nucleophile)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 70 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:780544 HCAPLUS
DOCUMENT NUMBER: 141:301421
TITLE: Improved bioavailability and improved delivery of alkaline drugs
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080468	A1	20040923	WO 2004-US6699	20040305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040214215	A1	20041028	US 2004-792273	20040304
AU 2004220597	A1	20040923	AU 2004-220597	20040305
CA 2517782	A1	20040923	CA 2004-2517782	20040305
EP 1601366	A1	20051207	EP 2004-717955	20040305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.:
US 2003-452557P P 20030307
US 2004-792273 A 20040304
WO 2004-US6699 A 20040305

OTHER SOURCE(S): MARPAT 141:301421

AB Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition The compns. include a mol. complex formed between an alkaline pharmaceutical and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof. The compns. provide improved bioavailability and improved delivery of the drug into the cutaneous tissues. For example, diphenhydramine hydrochloride 29 g (0.1 mol) was dissolved in water (50 mL) and 5N sodium hydroxide (20 mL) was slowly added to generate diphenhydramine as a free base as shown by the formation of oily ppts. and the change from pH 5.5 to 9.4. Gluconolactone 18 g (0.1 mol) was added to form a mol. complex between the diphenhydramine free base and gluconic acid/gluconolactone as shown by the disappearance of the oily ppts. and the change from pH 9.4 to 7.4. The solution thus obtained contained 0.1 mol diphenhydramine in mol. complex with 0.1 mol gluconic acid/gluconolactone. This concentrated stock solution was used for various forms of topical formulations including oil-in-water creams, lotions, gels and solns.

IT 132539-06-1, Olanzapine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improved bioavailability and improved delivery of alkaline drugs using hydroxy acids)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 71 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:486383 HCAPLUS
DOCUMENT NUMBER: 141:33816
TITLE: Controlled-release pharmaceuticals for prolonged suppression of electrical activity in excitable tissues, and use in the treatment of epilepsy and other conditions
INVENTOR(S): Kohane, Daniel S.; Langer, Robert S.
PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA; The General Hospital Corporation
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004050034	A2	20040617	WO 2003-US38406		20031202
WO 2004050034	A3	20050428			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003298837	A1	20040623	AU 2003-298837		20031202
US 20050202093	A1	20050915	US 2003-727032		20031202
PRIORITY APPLN. INFO.:			US 2002-430240P	P	20021202
			WO 2003-US38406	W	20031202

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB Controlled release of pharmaceutical agents using microspheres or other controlled release systems are used to treat disease state characterized by aberrant elec. activity in excitable tissue. For the treatment of epilepsy, agents useful in the treatment of epilepsy may be delivered to the patient at the site of seizure origin to control seizure activity in a time release manner. The system may also be useful in the treatment of cardiac arrhythmias and preterm labor. Particularly useful pharmaceutical compns. comprising a site 1 sodium channel blocker are also provided.
IT 132539-06-1, Zyprexa
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release pharmaceuticals for prolonged suppression of elec. activity in excitable tissues, and use in treatment of epilepsy and other conditions)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 72 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:354769 HCAPLUS
DOCUMENT NUMBER: 140:344947
TITLE: Pharmaceutical formulation of olanzapine
INVENTOR(S): Perc, Stanka; Banko, Ivanka; Kolenc, Ivanka
PATENT ASSIGNEE(S): Krka, Tovarna Zdravil D.D. Novo Mesto, Slovenia
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035027	A1	20040429	WO 2003-SI36	20031016
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
SI 21303	A	20040430	SI 2002-255	20021018
CA 2502582	A1	20040429	CA 2003-2502582	20031016
AU 2003269792	A1	20040504	AU 2003-269792	20031016
EP 1558219	A1	20050803	EP 2003-751723	20031016
EP 1558219	B1	20071003		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 374600	T	20071015	AT 2003-751723	20031016
PT 1558219	E	20080104	PT 2003-751723	20031016
ES 2295626	T3	20080416	ES 2003-751723	20031016
US 20050288276	A1	20051229	US 2005-531540	20050415
NO 2005002408	A	20050704	NO 2005-2408	20050513
PRIORITY APPLN. INFO.:			SI 2002-255 A	20021018
			WO 2003-SI36 W	20031016

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB A pharmaceutical formulation comprising a homogeneous mixture of (a) olanzapine or a pharmaceutically acceptable salt thereof as an active ingredient, (b) a monosaccharide and/or oligosaccharide, (c) a polysaccharide and, optionally, further ingredients.
IT 132539-06-1, Olanzapine
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmaceutical formulation of olanzapine)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 73 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:333612 HCAPLUS
DOCUMENT NUMBER: 140:362998
TITLE: Gamma irradiation of solid nanoparticulate active agents
INVENTOR(S): Lee, Robert; Hilborn, Matthew; Kline, Laura; Keller, Janine
PATENT ASSIGNEE(S): Elan Pharma International Limited, Ire.
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032980	A1	20040422	WO 2003-US27484	20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500908	A1	20040422	CA 2003-2500908	20030904
AU 2003268380	A1	20040504	AU 2003-268380	20030904
EP 1556091	A1	20050727	EP 2003-749342	20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006501936	T	20060119	JP 2004-543261	20030904

PRIORITY APPLN. INFO.:		
US 2002-415749P	P	20021004
WO 2003-US27484	W	20030904

AB The present invention relates to methods for terminal sterilization of solid forms of nanoparticulate active agent compns. via gamma irradiation The nanoparticulate active agent has an effective average particle size of less than about 2 μ, prior to incorporation into a solid form for sterilization. The resultant sterilized compns. exhibit excellent redispersibility, homogeneity, and uniformity. Also encompassed are compns. made via the described method and methods of treating animals and humans using such compns. Several examples are provided of γ-ray sterilization of naproxen nanoparticulate formulations. Pre-lyophilization, post-lyophilization and post-γ-irradiation properties (particle size, stability, osmolality, pH, microbiol. testing) are described. Surface stabilizers are used.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ-ray sterilization of pharmaceutical nanoparticles)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	7	THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT:	7	THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 74 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:189459 HCAPLUS
DOCUMENT NUMBER: 140:412427
TITLE: Batch and flow-injection methods for the spectrophotometric determination of olanzapine
AUTHOR(S): Jasinska, A.; Nalewajko, E.
CORPORATE SOURCE: Institute of Chemistry, University of Bialystok, ul. Hurtowa 1, Bialystok, 15-399, Pol.
SOURCE: Analytica Chimica Acta (2004), 508(2), 165-170
CODEN: ACACAM; ISSN: 0003-2670
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB An indirect batch spectrophotometric and direct flow-injection (FI) visible spectrophotometric methods was developed for the determination of the novel anti-psychotic drug olanzapine (OLA). The batch method was based on the oxidation of olanzapine by a known excess of potassium hexacyanoferrate(III) in the presence of the mixture of sulfuric and phosphoric acids (1:1 (volume/volume)). The absorbance of unreacted oxidant is measured at 425 nm. The absorbance decreases linearly with increasing concentration of the assayed drug. The FI method with detection at 540 nm is based on the direct oxidation of olanzapine one of two oxidants, cerium(IV) sulfate or potassium hexacyanoferrate(III) in acidic medium. The calibration graph were linear over the range of 2.5-40 μg ml-1 in the batch method and 0.05-300 and 0.5-250 μg ml-1 in the FI methods, used cerium (IV) sulfate and potassium hexacyanoferrate (III) resp. Both FI methods gave similar results in terms of precision and accuracy. The relative standard deviation (R.S.D.), was <1%. The accuracy, obtained from recovery expts., was 97.9-99.4%. The batch method gave slightly higher R.S.D. values (up to 2.3%) and lower values of accuracy (the recovery was between 96.5 and 96.6%). The methods developed were applied to the determination of olanzapine in a pharmaceutical product.

IT 132539-06-1, Zyprexa
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(batch and flow-injection methods for the spectrophotometric determination of olanzapine)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	10	THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
REFERENCE COUNT:	15	THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 75 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:60341 HCAPLUS
DOCUMENT NUMBER: 140:117406
TITLE: Liquid dosage compositions of stable nanoparticulate drugs
INVENTOR(S): Bosch, William H.; Hilborn, Matthew R.; Hovey, Douglas C.; Kline, Laura J.; Lee, Robert W.; Pruitt, John D.; Ryde, Niels P.; Ryde, Tuula A.; Xu, Shuqian
PATENT ASSIGNEE(S): Elan Pharma International, Ltd, Ire.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 25
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006959	A1	20040122	WO 2003-US22187	20030716
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492488	A1	20040122	CA 2003-2492488	20030716
AU 2003261167	A1	20040202	AU 2003-261167	20030716
EP 1551457	A1	20050713	EP 2003-764723	20030716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005536512	T	20051202	JP 2004-521891	20030716

PRIORITY APPLN. INFO.:
US 2002-396530P P 20020716
WO 2003-US22187 W 20030716

AB The present invention relates to liquid dosage compns. of stable nanoparticulate drugs. The liquid dosage compns. of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the drug. Thus, an aqueous nanoparticulate colloidal dispersion (NCD) comprising drug 32.5 Copovidone 6.5, and dioctyl sodium sulfosuccinate 0.464% by weight was prepared by milling for 3.8 h under high energy milling conditions. The final mean particle size (by weight) of the drug particles was 161 nm. The concentrated NCD was then diluted with preserved water and glycerol (the osmotically active crystal growth inhibitor) to 0.5-3.0% drug.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	6	THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT:	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 76 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:836821 HCAPLUS
DOCUMENT NUMBER: 139:328361
TITLE: Rapidly dispersing solid oral compositions
INVENTOR(S): Divi, Muralikrishna; Deshmukh, Abhijit Mukund; Dhanorkar, Vipin Tatyasaheb; Mohan, Mailatur Sivaraman
PATENT ASSIGNEE(S): Reddy's Laboratories Ltd., India
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003086361	A1	20031023	WO 2002-IB1272	20020418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002255196	A1	20031027	AU 2002-255196	20020418
PRIORITY APPLN. INFO.:			WO 2002-IB1272 A	20020418

AB The present invention relates to the rapidly dispersing solid oral compns. comprising olanzapine or ondansetron. The present invention further discloses the wet granulation or direct compression method of producing such rapidly dispersing compns. The pharmaceutically accepted solvate, salts, enantiomers or mixts. thereof including racemic mixture of olanzapine and ondansetron are contemplated to be within the scope of the present invention. For example, a rapidly dispersing tablet was formulated containing ondansetron 4, microcryst. cellulose 16.5, mannitol 2.5, pregelatinized starch 2.5, Crospovidone 5, aspartame 2, colloidal silica 1, Mg stearate 0.5, Avicel 112 12.85, Avicel CE15 2.5, Na lauryl sulfate 0.15, and strawberry flavor 0.5 mg/each.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rapidly dispersing solid oral compns.)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	4	THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 77 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:417599 HCAPLUS
DOCUMENT NUMBER: 138:406951
TITLE: Particulate compositions for improving solubility of poorly soluble drugs
INVENTOR(S): Batycky, Richard P.; Grandolfi, George; Plunkett, Sean; Lipp, Michael M.; Wright, James
PATENT ASSIGNEE(S): Advanced Inhalation Research, Inc., USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003043603	A1	20030530	WO 2002-US37413		20021120
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002346472	A1	20030610	AU 2002-346472		20021120
US 20030129250	A1	20030710	US 2002-300726		20021120
PRIORITY APPLN. INFO.:			US 2001-331810P	P	20011120
			WO 2002-US37413	W	20021120

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The invention is drawn to particles for oral drug delivery produced by spray-drying a dilute solution of a poorly soluble agent. The particles comprise regions of poorly soluble agent wherein the dissoln. rate enhancement is between about 2-fold and about 25-fold compared to the agent in bulk form. Examples drugs spray dried and tested for dissoln. were danazol, glyburide, glipizide, piroxicam, olansoprazole and ketoprofen.
IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(particulate compns. for improving solubility of poorly soluble drugs)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 78 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:261635 HCAPLUS
DOCUMENT NUMBER: 138:276289
TITLE: Process for the preparation of fast dissolving dosage form
INVENTOR(S): Madan, Ashish; Trehan, Anupam; Arora, Vinod Kumar
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026610	A2	20030403	WO 2002-IB3969	20020925
WO 2003026610	A3	20030626		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2001DE00981	A	20080725	IN 2001-DE981	20010925
CA 2461042	A1	20030403	CA 2002-2461042	20020925
AU 2002341241	A1	20030407	AU 2002-341241	20020925
EP 1432410	A2	20040630	EP 2002-775024	20020925
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012807	A	20041005	BR 2002-12807	20020925
CN 1578657	A	20050209	CN 2002-821667	20020925
JP 2005519865	T	20050707	JP 2003-530247	20020925
US 20040258748	A1	20041223	US 2004-490398	20040817
PRIORITY APPLN. INFO.:			IN 2001-DE981 A	20010925
			WO 2002-IB3969 W	20020925

AB A process for the preparation of fast dissolving/disintegrating tablets, wherein the porosity is produced by in situ gas generation through moisture activation of the tablets containing effervescent mixture is described.

The process comprises steps of (i) compression of a blend of a pharmaceutical active ingredient and about 1-35% by weight of an effervescent mixture containing an acid source and a base to produce tablets, (ii) moisture activation of the tablets by exposure to controlled humidity or controlled heating, and (iii) removal of the moisture by subjecting tablets to vacuum. For example, simvastatin mouth-soluble tablets were prepared containing simvastatin 5.0, BTA 0.25, mannitol 29.75, directly compressible lactose 40.0, hydroxypropyl cellulose 6.0, sodium bicarbonate 15.0, citric acid 15.0, aspartame 5.0, flavor 2.0, and magnesium stearate 2.0 mg, resp.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of fast dissolving tablets using effervescent mixture and moisture activation)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 79 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:555334 HCAPLUS
DOCUMENT NUMBER: 137:114525
TITLE: Syntactic deformable pharmaceutical foam compositions
INVENTOR(S): Odidi, Isa; Odidi, Amina
PATENT ASSIGNEE(S): Can.
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002056861	A2	20020725	WO 2002-CA54	20020117
WO 2002056861	A3	20021017		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6800668	B1	20041005	US 2001-765783	20010119
CA 2435276	A1	20020725	CA 2002-2435276	20020117
CA 2435276	C	20050315		
AU 2002226223	A1	20020730	AU 2002-226223	20020117
PRIORITY APPLN. INFO.:			US 2001-765783 A	20010119
			WO 2002-CA54 W	20020117

AB The invention relates to methods for preparing a syntactic foam composition suitable for use as a carrier for chems. or other compds., including pharmaceuticals. Carbopol 971P, hydroxyethyl cellulose, cellulose microspheres and silica, was mixed in a high-shear mixer. The resulting admixt. was treated with 2-propanol, while simultaneously subjecting the admixt. to high-shear forces in the high-shear mixer. This mixing created a uniform stable syntactic deformable and compressible dendritic solid foam which could be shaped before drying. Metoprolol succinate was added to the above admixt. and subjected to high-shear agitation for 2 min before treatment with 2-propanol. A stable syntactic deformable and compressible dendritic solid foam which could be shaped before drying was obtained. This was dried at 40°. The dried foam was the disentangled by size reduction to obtain discrete particles. The free flowing particles were reassembled and shaped by compression in a mold. The shaped units, when subjected to an aqueous medium, released metoprolol over a period of ≤3 h.
IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(syntactic deformable pharmaceutical foam compns.)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 80 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:487335 HCAPLUS
DOCUMENT NUMBER: 137:68153
TITLE: Novel in-situ forming polymer-based controlled release microcarrier delivery systems
INVENTOR(S): Bhagwatwar, Harshal Prabhakar; Bapat, Varada Ramesh; Paithankar, Mahesh Balkrishna; Yeola, Bhushan Subhash; Gosavi, Arun Shriniwas; Bagool, Manoj Anil; Shetty, Nitin; Shukla, Milind Chintaman; De Souza, Noel John; Khorakiwala, Habil Fakhruddin
PATENT ASSIGNEE(S): India
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049573	A2	20020627	WO 2001-IN219	20011214
WO 2002049573	A3	20030130		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030049320	A1	20030313	US 2001-23427	20011212
CA 2436149	A1	20020627	CA 2001-2436149	20011214
AU 2002022505	A	20020701	AU 2002-22505	20011214
EP 1363556	A2	20031126	EP 2001-271193	20011214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
IN 2003MN00505	A	20070316	IN 2003-MN505	20030512
PRIORITY APPLN. INFO.:			US 2000-256319P P	20001218
			WO 2001-IN219 W	20011214

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A ready-to use, stable, gelled polymer droplet-in-oil dispersion is described which helps in in-situ formation of a multitude of small solid, semisolid, or gelled microcarriers. The dispersion is placed into a body in a semisolid form and cures to form the delivery system in-situ. The process for making such a dispersion comprises the steps of (i) dissolving a polymer in a biocompatible solvent at an elevated temperature to form a polymer solution, (ii) preparing a second oil phase solution of a biocompatible emulsifier at an elevated temperature, (iii) mixing the polymer solution with the oil phase solution at an elevated temperature and subsequently cooling to refrigeration temperature Placing the gelled dispersion within a body produces the microcarrier delivery system in-situ. The composition of a syringeable, biodegradable dispersion incorporating an effective level of a biol. active agent before injection into a body provides a novel controlled delivery system of drugs for health-care applications. Thus, Poly(DL-lactide-co-glycolide) was dissolved in DMSO to form a polymer

solution of a 30% weight/weight concentration To this solution was added leuprolide acetate
to form a 10% weight/weight solution of the drug with respect to the polymer. The
polymer solution was injected by into a continuous oil phase comprising a 20% weight/weight solution of sorbitan monostearate (Arlacel 60) in super refined sesame seed oil maintained at 70-75°, accompanied by high speed homogenization at 13,000 rpm, for 3 min. The resulting polymer droplet-in-oil dispersion was cooled to room temperature with continuous mixing to obtain an opaque mass with a gel-like consistency, which did not flow. The gel was stored under refrigerated conditions until further use. The gel was smooth to the touch with an absence of any gritty particles. Microscopic observation of the gel revealed discrete distorted blue colored droplets of the discontinuous phase dispersed within the continuous oil phase.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in-situ forming polymer-based controlled release microcarrier delivery systems)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 81 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:465744 HCAPLUS
DOCUMENT NUMBER: 137:37658
TITLE: Process for the preparation of a fast dissolving dosage form
INVENTOR(S): Murpani, Deepak; Malik, Rajiv
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047607	A2	20020620	WO 2001-IB2354	20011207
WO 2002047607	A3	20030320		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 192750	A1	20040515	IN 2000-DE1170	20001215
AU 2002020968	A	20020624	AU 2002-20968	20011207
EP 1343481	A2	20030917	EP 2001-270300	20011207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: IN 2000-DE1170 A 20001215
WO 2001-IB2354 W 20011207

AB The present invention relates to a process for the preparation of fast dissolving dosage form, such as tablet, which disintegrates quickly in the mouth. The process of this invention is particularly suitable for moisture sensitive, poorly compressible and bitter drugs having a taste mask coating. A table composition contained rofecoxib 25.0, Aspartame 1.0, orange flavor 2.0, Croscarmellose sodium 9.0, PEG 8000 60.0, and sorbitol 233.0 mg.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of a fast dissolving dosage form)

RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	6	THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT:	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 82 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:525912 HCAPLUS
DOCUMENT NUMBER: 135:112000
TITLE: Osmotic device containing venlafaxine and an anti-psychotic agent
INVENTOR(S): Faour, Joaquina; Vergez, Juan A.
PATENT ASSIGNEE(S): Laboratorios Phoenix U.S.A., Inc., USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051041	A1	20010719	WO 2001-US580	20010108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20010048943	A1	20011206	US 2000-728276	20001130
US 6572890	B2	20030603		
CA 2396156	A1	20010719	CA 2001-2396156	20010108
CA 2396156	C	20080812		
CA 2614647	A1	20010719	CA 2001-2614647	20010108
EP 1246614	A1	20021009	EP 2001-901877	20010108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20030219483	A1	20031127	US 2003-377173	20030226
US 7008641	B2	20060307		

PRIORITY APPLN. INFO.:			
US 2000-175822P	P	20000113	
US 2000-728276	A	20001130	
CA 2001-2396156	A3	20010108	
WO 2001-US580	W	20010108	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The present invention provides an osmotic device containing controlled release venlafaxine in the core in combination with an anti-psychotic agent in a rapid release external coat. A wide range of anti-psychotic agents can be used in this device. Particular embodiments of the invention provide osmotic devices having predetd. release profiles. One embodiment of the osmotic device includes an external coat that has been spray-coated rather compression-coated onto the device. The device with spray-coated external core is smaller and easier to swallow than the similar device having a compression-coated external coat. The device is useful for the treatment of depression anxiety or psychosis related disorders. Thus, a core formulation contained venlafaxine 10-500, osmagent 17-250, binder 7.5-50, plasticizer (low mol. weight) 0.1-25, glidant 0.1-6, plasticizer (high mol. weight) 2.5-30, and lubricant 1-7.5 mg. Water soluble polymers were used in the coating formulations.
IT 132539-06-1, Olanzapine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(osmotic device containing venlafaxine and anti-psychotic agent)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	7	THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 83 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:525911 HCAPLUS
DOCUMENT NUMBER: 135:111999
TITLE: Osmotic device containing alprazolam and an antipsychotic agent
INVENTOR(S): Faour, Joaquina; Vergez, Juan A.
PATENT ASSIGNEE(S): Laboratorios Phoenix U.S.A., Inc., USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051040	A1	20010719	WO 2001-US637	20010109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020051807	A1	20020502	US 2001-756497	20010108
US 6599532	B2	20030729		
CA 2396214	A1	20010719	CA 2001-2396214	20010109
PRIORITY APPLN. INFO.:			US 2000-175827P P	20000113
			WO 2001-US637 W	20010109

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention provides an osmotic device containing controlled release alprazolam in the core optionally in combination with an anti-psychotic agent, in a rapid release external coat. A wide range of anti-psychotic agents can be used in this device. Particular embodiments of the invention provide osmotic devices having predetd. release profiles. One preferred embodiment of the osmotic device includes an external coat that has been spray coated rather than compression coated onto the device. The device with spray coated external coat is smaller and easier to swallow than the similar device having a compression coated external coat. The device is useful for the treatment of depression, anxiety or psychosis related disorders. Thus, osmotic-release tablets contained alprazolam 2.000, Polysorbate-20 2.800, microcryst. cellulose 116.800, NaCl 228.000, Povidone 60.000, PEG 160.000, HPMC-2208 14.000, colloidal SiO2 7.600, and Mg. The coating formulation also contained risperidone 5.000 mg.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(osmotic device containing alprazolam and antipsychotic agent)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	7	THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 84 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:396652 HCAPLUS
DOCUMENT NUMBER: 135:10023
TITLE: Preparation of coated tablets
INVENTOR(S): Entner, Reinhard; Jennewein, Herwig
PATENT ASSIGNEE(S): Biochemie Gesellschaft M.B.H., Austria
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037816	A2	20010531	WO 2000-EP11590	20001121
WO 2001037816	A3	20011129		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AT 500063	A1	20051015	AT 1999-1988	19991123
TW 579298	B	20040311	TW 2000-89124406	20001117
CA 2387575	A1	20010531	CA 2000-2387575	20001121
BR 2000015449	A	20020709	BR 2000-15449	20001121
EP 1231903	A2	20020821	EP 2000-987277	20001121
EP 1231903	B1	20060111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
TR 200201028	T2	20021021	TR 2002-1028	20001121
JP 2003514848	T	20030422	JP 2001-539431	20001121
HU 2002004072	A2	20030528	HU 2002-4072	20001121
HU 2002004072	A3	20040628		
NZ 518524	A	20040430	NZ 2000-518524	20001121
AU 776662	B2	20040916	AU 2001-23585	20001121
AT 315383	T	20060215	AT 2000-987277	20001121
ES 2255521	T3	20060701	ES 2000-987277	20001121
ZA 2002003654	A	20030605	ZA 2002-3654	20020508
NO 2002002362	A	20020711	NO 2002-2362	20020516
MX 2002005195	A	20030128	MX 2002-5195	20020523
US 20060034917	A1	20060216	US 2005-233121	20050922

PRIORITY APPLN. INFO.:		
AT 1999-1988	A	19991123
EP 2000-987277	A	20001121
WO 2000-EP11590	W	20001121
US 2002-130650	A1	20020923

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB A process for the coating of tablet cores, in which the tablet core comprises at least 1 drug, consists of spraying a coating solution or a suspension containing a sugar, or a starch, or a mixture of a sugar and a starch
onto the tablets or tablet cores with the proviso that film-forming agents in the coating solution or suspension are excluded. Thus, tablet cores were

prepared from cefuroxime axetil 608, microcryst. cellulose 110, Ac-Di-Sol 80, and Mg stearate 4 mg. The tableted material was sieved and mixed with Crospovidone 60, Aerosil-200 6, talc 20, Mg stearate 4, and Texapon 9 mg. Tablet cores thus obtained were coated with a mixture containing mannitol 33.2, starch 10.0, lactose 19.9, talc 21.2, TiO2 14.1, aspartame 1.4, and Texapon 0.2%.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of coated tablets)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 85 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:861488 HCAPLUS
DOCUMENT NUMBER: 134:32979
TITLE: Therapeutic use of melatonin in treatment of tardive dyskinesia
INVENTOR(S): Zisapel, Nava; Laudon, Moshe
PATENT ASSIGNEE(S): Neurim Pharmaceuticals (1991) Ltd., Israel
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000072843	A1	20001207	WO 2000-IL296	20000524
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IL 130171	A	20040601	IL 1999-130171	19990527
CA 2374129	A1	20001207	CA 2000-2374129	20000524
EP 1183024	A1	20020306	EP 2000-929756	20000524
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 2002001405	A2	20020828	HU 2002-1405	20000524
HU 2002001405	A3	20031128		
JP 2003500446	T	20030107	JP 2000-620955	20000524
EE 200100623	A	20030217	EE 2001-623	20000524
NZ 515866	A	20030530	NZ 2000-515866	20000524
BR 2000017329	A	20030729	BR 2000-17329	20000524
AU 775520	B2	20040805	AU 2000-47756	20000524
CN 1176652	C	20041124	CN 2000-808106	20000524
TR 200103418	T2	20041221	TR 2001-3418	20000524
TW 236906	B	20050801	TW 2000-89110619	20000531
MX 2001012040	A	20030904	MX 2001-12040	20011123
NO 2001005738	A	20020125	NO 2001-5738	20011126
NO 319421	B1	20050808		
US 6566389	B1	20030520	US 2001-979583	20011126
BG 106234	A	20020830	BG 2001-106234	20011218
IN 2001DN01161	A	20070112	IN 2001-DN1161	20011218
ZA 2001010436	A	20040331	ZA 2001-10436	20011220
IN 2002DN00171	A	20091030	IN 2002-DN171	20020212
HK 1047048	A1	20050527	HK 2002-108721	20021129

PRIORITY APPLN. INFO.:
IL 1999-130171 A 19990527
WO 2000-IL296 W 20000524
IN 2001-DN1161 A3 20011218

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to a method for preventing or treating symptoms of tardive dyskinesia in a patient, by administering an effective amount of melatonin for this purpose, and to a pharmaceutical formulation which

comprises at least one neuroleptic compound in an amount effective to exert a neuroleptic effect in a patient requiring such treatment, and melatonin in an amount effective to ameliorate, or prevent the development of symptoms of tardive dyskinesia. For example, controlled-release tablets were prepared containing chlorpromazine hydrochloride 275 mg/tablet, melatonin 5 mg/tablet, and Eudragit RS 100 carrier and lactose mixture (1:1). It is contemplated that 2 such tablets taken 2 h before bedtime would be appropriate.

IT 132539-06-1, Olanzapine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing melatonin and neuroleptic for treatment of tardive dyskinesia)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 86 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:861473 HCAPLUS
DOCUMENT NUMBER: 134:32972
TITLE: Porous drug matrixes containing polymers and sugars and methods of their manufacture
INVENTOR(S): Straub, Julie; Bernstein, Howard; Chickering, Donald E., III; Khatak, Sarwat; Randall, Greg
PATENT ASSIGNEE(S): Acusphere, Inc., USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000072827	A2	20001207	WO 2000-US14578	20000525
WO 2000072827	A3	20010125		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6395300	B1	20020528	US 1999-433486	19991104
CA 2371836	A1	20001207	CA 2000-2371836	20000525
CA 2371836	C	20060131		
EP 1180020	A2	20020220	EP 2000-939365	20000525
EP 1180020	B1	20051214		
EP 1180020	B2	20090624		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
BR 2000010984	A	20020430	BR 2000-10984	20000525
JP 2003500438	T	20030107	JP 2000-620939	20000525
NZ 516083	A	20030829	NZ 2000-516083	20000525
AU 768022	B2	20031127	AU 2000-54459	20000525
AT 312601	T	20051215	AT 2000-939365	20000525
EP 1642572	A1	20060405	EP 2005-27194	20000525
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
ES 2250141	T3	20060416	ES 2000-939365	20000525
TW 274589	B	20070301	TW 2000-89110363	20000529
US 20020041896	A1	20020411	US 2001-798824	20010302
US 6610317	B2	20030826		
KR 752000	B1	20070828	KR 2001-715052	20011124
NO 2001005753	A	20020128	NO 2001-5753	20011126
NO 323761	B1	20070702		
MX 2001012106	A	20030630	MX 2001-12106	20011126
ZA 2001010347	A	20030730	ZA 2001-10347	20011218
HK 1048956	A1	20060728	HK 2003-101310	20030220
US 40493	E1	20080909	US 2005-213257	20050826
PH 1200600163	A	20090824	PH 2006-1200600163	20060322
HK 1094775	A1	20080822	HK 2007-102209	20070227
KR 2007069219	A	20070702	KR 2007-712286	20070531

KR 883477 B1 20090216
PRIORITY APPLN. INFO.: US 1999-136323P P 19990527
US 1999-158659P P 19991008
US 1999-433486 A 19991104
US 2000-186310P P 20000302
EP 2000-939365 A3 20000525
WO 2000-US14578 W 20000525
PH 2000-1200001402 A3 20000529
US 2001-798824 E 20010302
KR 2001-715052 A3 20011124
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form,
preferably microparticles, which enhances dissoln. of the drug in aqueous media. The drug matrixes preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in
a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solns., and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray
drying is used to remove the solvents and the pore forming agent.
The resulting porous matrix has a faster rate of dissoln. following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration. Paclitaxel or docetaxel can be provided in a porous matrix form, which allows the drug to be formulated without solubilizing agents and administered as a bolus. For example, a nifedipine-loaded organic solution was prepared by dissolving 9.09 g of PEG 3350, 2.27 g of nifedipine, and 0.009 g of lecithin in 182 mL of methylene chloride. An aqueous solution was
prepared by dissolving 3.27 g of NH4HCO3 and 0.91 g of PEG 3350 in 1.82 mL of water. The aqueous and organic solns. were homogenized and resulting emulsion
was spray dried. A suspension of the porous nifedipine drug matrix was prepared in 5% dextrose solution at a concentration of 2.5 mg/mL. A bolus injection
of the suspension was tolerated when administrated to dogs.
IT 132539-06-1, Olanzapine
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(preparation of porous matrixes containing hydrophilic polymers and sugars for
enhancement of drug dissoln.)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	31	THERE ARE 31 CAPLUS RECORDS THAT CITE THIS RECORD (31 CITINGS)
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 87 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:233762 HCAPLUS
DOCUMENT NUMBER: 130:257362
TITLE: Methylthienobenzodiazepine derivative antipsychotic drug formulation.
INVENTOR(S): Allen, Douglas James; Dekemper, Kurt Douglas; Ferguson, Thomas Harry; Garvin, Stuart James; Murray, Linda Cameron; Brooks, Norman Dale; Bunnell, Charles Arthur; Hendriksen, Barry Arnold; Mascarenhas, Snehlata Singh; Shinkle, Sharon Louise; Sanchez-Felix, Manuel Vicente; Tupper, David Edward
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9916313	A1	19990408	WO 1998-US20426	19980930
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2304568	A1	19990408	CA 1998-2304568	19980930
CA 2304568	C	20080812		
AU 9895914	A	19990423	AU 1998-95914	19980930
AU 752552	B2	20020919		
EP 1018880	A1	20000719	EP 1998-949632	19980930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9813228	A	20000829	BR 1998-13228	19980930
HU 2000004534	A2	20010528	HU 2000-4534	19980930
TR 200000812	T2	20010723	TR 2000-812	19980930
JP 2001517685	T	20011009	JP 2000-513467	19980930
NZ 503641	A	20020927	NZ 1998-503641	19980930
CN 1239158	C	20060201	CN 1998-809565	19980930
IL 135295	A	20061031	IL 1998-135295	19980930
CZ 300725	B6	20090729	CZ 2000-1162	19980930
MX 2000003040	A	20001110	MX 2000-3040	20000328
NO 2000001631	A	20000530	NO 2000-1631	20000329
HR 2000000181	A1	20001231	HR 2000-181	20000331
HR 2000000181	B1	20060731		
US 20030027816	A1	20030206	US 2002-136887	20020501
US 6617321	B2	20030909		
US 20040097489	A1	20040520	US 2003-613619	20030703
US 7303764	B2	20071204		

PRIORITY APPLN. INFO.:		
US 1997-60493P	P	19970930
WO 1998-US20426	W	19980930
US 2000-509757	B1	20000329
US 2002-136887	A1	20020501

AB The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2.3-b][1.5]benzodiazepine (olanzapine) (preparation given) or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.

IT 132539-06-1P, Olanzapine 221373-09-7P
221373-12-2P 221373-14-4P 221373-18-8P
221373-22-4P 221373-25-7P 221373-29-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and formulation of)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 221373-09-7 HCAPLUS

CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



RN 221373-12-2 HCAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with methanol and 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



CM 3

CRN 67-56-1
CMF C H4 O

H_3C-OH

RN 221373-14-4 HCAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine and tetrahydrofuran (1:1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



CM 3

CRN 109-99-9
CMF C4 H8 O

RN 221373-18-8 HCAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, hydrate (1:1:1) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



RN 221373-22-4 HCAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine and 2-propanone (1:2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



CM 3

CRN 67-64-1
CMF C3 H6 O



RN 221373-25-7 HCAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:2), monohydrate (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



RN 221373-29-1 HCAPLUS
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:1), dihydrate (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 130-85-8
CMF C23 H16 O6



OS.CITING REF COUNT:	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 88 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1997:332391 HCAPLUS
DOCUMENT NUMBER: 126:308810
ORIGINAL REFERENCE NO.: 126:59765a,59768a
TITLE: Pharmaceutical compositions for treating a tic disorder
INVENTOR(S): Beasley, Charles M., Jr.
PATENT ASSIGNEE(S): Eli Lilly and Co., USA; Beasley, Charles M., Jr.
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9711700	A1	19970403	WO 1996-US14090	19960827
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM				
CA 2232559	A1	19970403	CA 1996-2232559	19960827
AU 9670131	A	19970417	AU 1996-70131	19960827
EP 852496	A1	19980715	EP 1996-931453	19960827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 11512705	T	19991102	JP 1996-513436	19960827
US 6274636	B1	20010814	US 1999-242418	19990216
PRIORITY APPLN. INFO.:			US 1995-5176P P	19950929
			WO 1996-US14090 W	19960827

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB A pharmaceutical composition for treating a tic disorder comprise administering an effective amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (preparation given) (I). A tablet contained I 10.0, magnesium stearate 0.9, microcryst. cellulose 75.0, povidone 25.0, and starch 204.1 mg.
IT 132539-06-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. for treating tic disorder)
RN 132539-06-1 HCAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 89 OF 89 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1996:660926 HCAPLUS
DOCUMENT NUMBER: 125:284960
ORIGINAL REFERENCE NO.: 125:53125a,53128a
TITLE: Oral olanzapine formulation
INVENTOR(S): Cochran, George Randall; Morris, Tommy Clifford
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 733367	A1	19960925	EP 1996-301997	19960322
EP 733367	B1	20011017		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
EG 24077	A	20080511	EG 1996-251	19960321
CA 2216372	A1	19961003	CA 1996-2216372	19960322
CA 2216372	C	20071120		
WO 9629995	A1	19961003	WO 1996-US3918	19960322
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9654280	A	19961016	AU 1996-54280	19960322
AU 696601	B2	19980917		
ZA 9602338	A	19970922	ZA 1996-2338	19960322
GB 2313783	A	19971210	GB 1997-19817	19960322
GB 2313783	B	19981118		
DE 19681287	T0	19980319	DE 1996-19681287	19960322
CN 1179102	A	19980415	CN 1996-192778	19960322
CN 1178662	C	20041208		
BR 9607791	A	19980707	BR 1996-7791	19960322
HU 9800410	A2	19980728	HU 1998-410	19960322
HU 9800410	A3	20000128		
HU 225269	B1	20060828		
AT 9609022	A	19990215	AT 1996-9022	19960322
AT 405606	B	19991025		
JP 11502848	T	19990309	JP 1996-529533	19960322
TW 426526	B	20010321	TW 1996-85103453	19960322
EP 1093815	A1	20010425	EP 2000-204708	19960322
EP 1093815	B1	20041215		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
CH 691217	A5	20010531	CH 1997-2246	19960322
AT 206924	T	20011115	AT 1996-301997	19960322
EE 3551	B1	20011217	EE 1997-328	19960322
ES 2164837	T3	20020301	ES 1996-301997	19960322
PT 733367	E	20020328	PT 1996-301997	19960322
IL 117611	A	20020523	IL 1996-117611	19960322
RO 118370	B1	20030530	RO 1997-1776	19960322
SK 283745	B6	20031202	SK 1997-1282	19960322

AT 284695	T	20050115	AT 2000-204708		19960322
PL 188316	B1	20050131	PL 1996-322579		19960322
PT 1093815	E	20050331	PT 2000-204708		19960322
ES 2232379	T3	20050601	ES 2000-204708		19960322
CZ 296007	B6	20051214	CZ 1997-3001		19960322
IN 1996CA00517	A	20060113	IN 1996-CA517		19960322
SE 9703206	A	19970905	SE 1997-3206		19970905
LT 4350	B	19980525	LT 1997-149		19970916
FI 9703749	A	19970922	FI 1997-3749		19970922
NO 9704363	A	19971117	NO 1997-4363		19970922
NO 320388	B1	20051128			
DK 9701090	A	19971112	DK 1997-1090		19970923
DK 173323	B1	20000724			
LV 11983	B	19980720	LV 1997-199		19971014
IN 1999CA00416	A	20050311	IN 1999-CA416		19990504
IN 2007KO00577	A	20071026	IN 2007-KO577		20070413
PRIORITY APPLN. INFO.:			US 1995-410465	A	19950324
			EP 1996-301997	A3	19960322
			IN 1996-CA517	A3	19960322
			WO 1996-US3918	W	19960322

AB The invention provides a pharmaceutically elegant solid oral formulation of olanzapine and a process for making such formulation. The formulation comprises olanzapine as an active ingredient intimately mixed with a bulking agent, binder, disintegrant, and a lubricant; wherein such solid oral formulation is coated with a polymer selected from the group consisting of hydroxypropyl Me cellulose, sodium CM-cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, dimethylaminoethyl methacrylate-Me acrylate copolymer, Et acrylate-Me methacrylate copolymer, Me cellulose, and Et cellulose. A tablet contained olanzapine 1, lactose 67.43, hydroxypropyl cellulose 3.4, Crospovidone 4.25, microcryst. cellulose 8.5, Mg stearate 0.42, hydroxypropyl Me cellulose (as subcoating agent) 1.7, color mixture (as coating agent) 3.47 mg/tablet, Carnauba wax (as polishing agent) trace, and edible Blue ink (for imprinting) trace.

IT 132539-06-1P, Olanzapine
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(oral olanzapine formulation)

RN 132539-06-1 HCAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)